

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/415, C07D 235/06</b>	A1	(11) International Publication Number: <b>WO 97/04771</b> (43) International Publication Date: 13 February 1997 (13.02.97)
(21) International Application Number: <b>PCT/GB96/01832</b>		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 30 July 1996 (30.07.96)		
(30) Priority Data: 9515843.2 2 August 1995 (02.08.95) GB 9611245.3 30 May 1996 (30.05.96) GB		
(71) Applicant ( <i>for all designated States except US</i> ): NEWCASTLE UNIVERSITY VENTURES LIMITED [GB/GB]; 18 Windsor Terrace, Jesmond, Newcastle upon Tyne NE2 4HE (GB).		Published <i>With international search report.</i>
(72) Inventors; and		
(75) Inventors/Applicants ( <i>for US only</i> ): GRIFFIN, Roger, John [GB/GB]; 6 St. Leonards Walk, Lancaster Park, Morpeth, Northumberland NE61 3SZ (GB). CALVERT, Alan, Hilary [GB/GB]; Beech House, Burn Road, Blaydon, Tyne and Wear NE21 6JR (GB). CURTIN, Nicola, Jane [GB/GB]; Vale View, Stirling Avenue, Rowlands Gill, Tyne and Wear NE39 1PK (GB). NEWELL, David, Richard [GB/GB]; The Dower House, Humshaugh, Hexham, Northumberland NE6 4AG (GB). GOLDING, Bernard, Thomas [GB/GB]; 6 The Copse, Burnopfield, Newcastle upon Tyne NE16 6HA (GB).		
(74) Agent: H.N. & W.S. SKERRETT; Charles House, 148/9 Great Charles Street, Birmingham B3 3HT (GB).		

(54) Title: BENZIMIDAZOLE COMPOUNDS



(57) Abstract

A range is disclosed of benzimidazole-4-carboxamide compounds (I) which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. In formula (I), R and R' may each be selected independently from hydrogen, alkyl, hydroxalkyl (e.g. CH<sub>2</sub>CH<sub>2</sub>OH), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group. R is generally a substituted phenyl group in the most preferred compounds. The compounds may also be used in the form of pharmaceutically acceptable salts or pro-drugs.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AM</b>	Armenia	<b>GB</b>	United Kingdom	<b>MW</b>	Malawi
<b>AT</b>	Austria	<b>GE</b>	Georgia	<b>MX</b>	Mexico
<b>AU</b>	Australia	<b>GN</b>	Guinea	<b>NE</b>	Niger
<b>BB</b>	Barbados	<b>GR</b>	Greece	<b>NL</b>	Netherlands
<b>BE</b>	Belgium	<b>HU</b>	Hungary	<b>NO</b>	Norway
<b>BF</b>	Burkina Faso	<b>IE</b>	Ireland	<b>NZ</b>	New Zealand
<b>BG</b>	Bulgaria	<b>IT</b>	Italy	<b>PL</b>	Poland
<b>BJ</b>	Benin	<b>JP</b>	Japan	<b>PT</b>	Portugal
<b>BR</b>	Brazil	<b>KE</b>	Kenya	<b>RO</b>	Romania
<b>BY</b>	Belarus	<b>KG</b>	Kyrgyzstan	<b>RU</b>	Russian Federation
<b>CA</b>	Canada	<b>KP</b>	Democratic People's Republic of Korea	<b>SD</b>	Sudan
<b>CF</b>	Central African Republic	<b>KR</b>	Republic of Korea	<b>SE</b>	Sweden
<b>CG</b>	Congo	<b>KZ</b>	Kazakhstan	<b>SG</b>	Singapore
<b>CH</b>	Switzerland	<b>LI</b>	Liechtenstein	<b>SI</b>	Slovenia
<b>CI</b>	Côte d'Ivoire	<b>LK</b>	Sri Lanka	<b>SK</b>	Slovakia
<b>CM</b>	Cameroon	<b>LR</b>	Liberia	<b>SN</b>	Senegal
<b>CN</b>	China	<b>LT</b>	Lithuania	<b>SZ</b>	Swaziland
<b>CS</b>	Czechoslovakia	<b>LU</b>	Luxembourg	<b>TD</b>	Chad
<b>CZ</b>	Czech Republic	<b>LV</b>	Larvia	<b>TG</b>	Togo
<b>DE</b>	Germany	<b>MC</b>	Monaco	<b>TJ</b>	Tajikistan
<b>DK</b>	Denmark	<b>MD</b>	Republic of Moldova	<b>TT</b>	Trinidad and Tobago
<b>EE</b>	Estonia	<b>MG</b>	Madagascar	<b>UA</b>	Ukraine
<b>ES</b>	Spain	<b>ML</b>	Mali	<b>UG</b>	Uganda
<b>FI</b>	Finland	<b>MN</b>	Mongolia	<b>US</b>	United States of America
<b>FR</b>	France	<b>MR</b>	Mauritania	<b>UZ</b>	Uzbekistan
<b>GA</b>	Gabon			<b>VN</b>	Viet Nam

BENZIMIDAZOLE COMPOUNDS

The present invention relates to certain benzimidazole compounds that are of interest as being at least potentially useful chemotherapeutic agents by virtue of an ability to inhibit the activity of the enzyme poly ADP-ribosyltransferase (EC 2.4.2.30), also known as poly(ADP-ribose) polymerase, commonly referred to as ADPRT or PARP. In general, the latter abbreviation, PARP, will be used throughout the present specification.

BACKGROUND

At least in higher organisms, the enzyme poly ADP-ribosyltransferase is known to catalyse a transfer of the ADP-ribose moiety from the oxidized form, NAD<sup>+</sup>, of nicotinamide adenine dinucleotide to nuclear acceptor proteins so as to form homo ADP-ribose polymers, and this process has been implicated in a number of cellular events such as, for example, repair of DNA damage, development of cellular differentiation, transformation of cells by oncogenes, and gene expression. A common feature in a number of these processes is the formation and repair of DNA strand breaks and the stage which involves the PARP enzyme appears to be that of DNA ligase II-mediated strand rejoining. In the majority of cases a role for poly ADP-ribosylation has been implicated by the use of inhibitors of the PARP enzyme, and this has led to suggestions that such inhibitors, by interfering with the intracellular DNA repair mechanism, may have a useful chemotherapeutic role insofar as they should be able to modify treatment resistance characteristics and potentiate or enhance the effectiveness of cytotoxic drugs in chemotherapy or of radiation in radiotherapy where a primary effect of the treatment is that of causing DNA damage in target cells, as for example in many forms of antitumour therapy.

In this connection, several classes of PARP

inhibitors are already known, including benzamide and various nicotinamide and benzamide analogues, especially 3-substituted benzamides with small substituent groups such as 3-amino, 3-hydroxy and 3-methoxy. PARP inhibitory activity of certain N-substituted benzamides has also been reported in EP-A-0305008 wherein it has also been proposed to use these compounds in medicine for increasing the cytotoxicity of radiation or of chemotherapeutic drugs.

10

Regarding this use of benzamide compounds as chemotherapeutic agents, various studies on such compounds that are known to exhibit PARP inhibitory activity have confirmed that they can potentiate the 15 cytotoxicity of a range of antitumour agents *in vitro*, for example, bleomycin and methylating drugs. More limited data has further indicated that such benzamide compounds can also potentiate the activity of cytotoxic drugs *in vivo*, although the dose requirements have appeared to be 20 rather high (e.g. in the region of 0.5g kg<sup>-1</sup> per dose for 3-aminobenzamide) and there may be associated problems in preparing satisfactory pharmaceutical formulations and in avoiding toxicity limitations. Furthermore, a number of the known benzamide compounds have also been shown 25 clearly to have potential as radiosensitizers, increasing for example ionising radiation-induced tumour cell kill both *in vitro* and *in vivo*, and it is believed that in many cases this effect is related to these compounds acting as PARP inhibitors and interfering with DNA 30 repair.

However, notwithstanding the existing data from *in vitro* and *in vivo* studies suggesting that PARP inhibitors have considerable potential as useful chemotherapeutic 35 agents which merit further clinical evaluation, for instance in connection with cancer therapy, currently available known PARP inhibitors are not considered as yet to be entirely suitable to represent candidate drugs and there remains a need to find and develop a greater range

of compounds having potentially useful PARP inhibitory properties.


5 DISCLOSURE OF THE INVENTION

The present invention identifies a new range or ranges of compounds of interest as PARP inhibitors that can be useful in medicine, especially when administered 10 in conjunction with at least certain cytotoxic drugs or with radiotherapy for increasing the cytotoxic effectiveness thereof. In general, the compounds to which this invention relates comprise certain benzimidazole derivatives, more particularly 15 benzimidazole-4-carboxamide compounds, as hereinbelow defined. By virtue of their structure it would appear that many such compounds are particularly well adapted to compete with the natural substrate NAD<sup>+</sup> for the PARP enzyme.

20

More specifically, from one aspect, the invention resides in the use of a compound as herein defined for the manufacture of a medical or veterinary preparation for use in therapy for inhibiting activity of the enzyme 25 poly(ADP-ribose)polymerase or PARP (also known as ADP-ribosyl transferase or ADPRT), such enzyme inhibition constituting an element of a therapeutic treatment, wherein said compound provides the active PARP enzyme 30 inhibiting agent and comprises a benzimidazole-4-carboxamide having the general structural formula I

35



I

or a pharmaceutically acceptable salt and/or pro-drug form thereof,

characterised in that in structural formula I

5

R is selected from hydrogen, alkyl, hydroxyalkyl (e.g. CH<sub>2</sub>CH<sub>2</sub>OH), acyl (e.g. acetyl or benzoyl) and an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group,  
10 and


10

R' is selected from hydrogen, alkyl, hydroxyalkyl (e.g. CH<sub>2</sub>CH<sub>2</sub>OH), acyl (e.g. acetyl or benzoyl) and an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group.

15

The invention also provides for use in therapy, as active pharmaceutical substances, especially but not exclusively as PARP inhibitors, benzimidazole compounds having the general structural formula I

20



I

25

(or a pharmaceutically acceptable salt and/or pro-drug form thereof), with substituents as defined above except for provisos that R' is not an optionally substituted aralkyl group and R does not represent 4'-methanesulphonyloxy-2'-methoxy-phenyl.

35

The invention further provides novel benzimidazole compounds having the general structural formula I (or a pharmaceutically acceptable salt and/or pro-drug form thereof), with substituents as defined above except for provisos that R' is not an optionally substituted aralkyl


group and R does not represent 4'-methanesulphonyloxy-2'-methoxy-phenyl or an unsubstituted aryl group such as phenyl.

5        Alkyl groups when present as such or as a moiety in other groups will generally be composed of 1-8 carbon atoms, preferably 1-6 carbon atoms, and more usually 1-4 carbon atoms. In particular, when R and/or R' is an alkyl group this will generally be C<sub>1-6</sub> alkyl, such as 10 for example methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl or cyclohexyl. When R and/or R' is or includes a phenyl group this may be substituted, especially in the 4 (para) position but alternatively or additionally in the 2-position and/or 3-position for instance, by various 15 substituents including hydroxy, alkoxy (methoxy or ethoxy for example), cyano, carboxy, amide, tetrazole, amino or substituted amino, CW<sub>3</sub> (e.g. CF<sub>3</sub>) or W where W is halogen.

20        In cases where R' is hydrogen or alkyl preferred compounds of structural formula I include compounds in which R is phenyl or benzyl having at least one substituent in the benzene ring which is selected from hydroxy, alkoxy, NO<sub>2</sub>, N<sub>3</sub>, NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub> and R<sub>6</sub> each being 25 independently hydrogen, alkyl or alkoxy), NHCOR<sub>3</sub> (R<sub>3</sub> being alkyl or aryl), CO<sub>2</sub>R<sub>4</sub> (R<sub>4</sub> being H or alkyl), an amide (e.g. CONH<sub>2</sub>), tetrazole, alkyl, hydroxyalkyl, CW<sub>3</sub> or W (W being halogen), and CN.

30        More particularly, where R represents a substituted phenyl group having the structural formula II

35



II


R<sub>1</sub>, R<sub>2</sub> and R<sub>9</sub> may be each selected independently from H,

hydroxy, alkoxy, NO<sub>2</sub>, N<sub>3</sub>, NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub> and R<sub>6</sub> each being independently hydrogen, alkyl or alkoxy), NHCOR<sub>3</sub> (R<sub>3</sub> being alkyl or aryl), CO<sub>2</sub>R<sub>4</sub> (R<sub>4</sub> being H or alkyl), an amide (e.g. CONH<sub>2</sub>), tetrazole, alkyl, hydroxyalkyl, CW<sub>3</sub> 5 or W (W being halogen), and CN.

The invention also includes a process for preparing a compound of structural formula I as specified above wherein R represents an optionally substituted phenyl 10 group having the structural formula II, said process comprising the steps of reacting an alkyl 2,3-diaminobenzoate with an aryl acid chloride, treating the product with acetic acid at an elevated temperature to bring about benzimidazole ring formation, and reacting 15 with liquid ammonia to form the amide derivative.

Where R' represents a substituted phenyl group having the structural formula III

20



25

R<sub>7</sub>, R<sub>8</sub> and R<sub>10</sub> may be each selected independently from H, hydroxy, alkoxy, NO<sub>2</sub>, N<sub>3</sub>, NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub> and R<sub>6</sub> each being independently hydrogen, alkyl or alkoxy), NHCOR<sub>3</sub> (R<sub>3</sub> being alkyl or aryl), CO<sub>2</sub>R<sub>4</sub> (R<sub>4</sub> being H or alkyl), an amide (e.g. CONH<sub>2</sub>), tetrazole, alkyl, hydroxyalkyl, CW<sub>3</sub> 30 or W (W being halogen), and CN.

35

Compounds of structural formula I as hereinabove defined which have an aromatic ring that includes a CN substituent may often also be particularly useful as intermediates in making other compounds in accordance

with the invention since a cyano substituent can generally be converted, using standard methodology, into a variety of other functional groups, including amine, carboxyl, amide and tetrazole.

5

Within the ranges of benzimidazole compounds disclosed herein, preferred members which are of particular interest include

- 10       (a) 2-methylbenzimidazole-4-carboxamide;
- (b) benzimidazole-4-carboxamide;
- (c) 2-phenylbenzimidazole-4-carboxamide;
- (d) 2-(4'-methoxyphenyl)benzimidazole-4-carboxamide;
- (e) 2-(4'-trifluoromethylphenyl)benzimidazole-4-
- 15        carboxamide;
- (f) 2-(4'-hydroxyphenyl)benzimidazole-4-carboxamide;
- (g) 2-trifluoromethylbenzimidazole-4-carboxamide;
- (h) 2-(4'-methoxyphenyl)-N-methylbenzimidazole-4-
- carboxamide;
- 20        (i) 2-(4'-nitrophenyl)benzimidazole-4-carboxamide;
- (j) 2-(4'-cyanophenyl)benzimidazole-4-carboxamide;
- (k) 2-(3'-trifluoromethylphenyl)benzimidazole-4-
- carboxamide;
- (l) 2-(3'-methoxyphenyl)benzimidazole-4-carboxamide;
- 25        (m) 2-(4'-methoxyphenyl)-1-N-benzoylbenzimidazole-4-
- carboxamide,
- (n) 2-(4'-aminophenyl)benzimidazole-4-carboxamide
- (o) 2-(2'-trifluoromethylphenyl)benzimidazole-4-
- carboxamide,
- 30        (p) N-carboxybenzyl-2-(4'-methoxyphenyl)-
- benzimidazole-4-carboxamide.

In the above-mentioned compounds of this invention wherein there is an electron-rich aromatic ring, it is believed that in at least some cases the carboxamide group may be constrained in a fixed conformation, particularly favourable for presenting the compound as an inhibitor of NAD<sup>+</sup> binding to the PARP enzyme, by an intramolecular hydrogen bond between an imidazole ring

nitrogen atom and one of the hydrogen atoms of the carboxamide group.

As already indicated, the invention also embraces  
5 or extends to methods of preparing compounds as hereinbefore defined (including intermediates in some cases) and to the therapeutic use of such compounds in treating mammals. This includes their use for making medical or veterinary preparations or pharmaceutical  
10 formulations containing an effective PARP inhibitory amount of the active compound for administration to a patient in conjunction with a cytotoxic drug or radiotherapy in order to increase the cytotoxic effectiveness of the latter. Such preparations or  
15 formulations may be made up in accordance with any of the methods well known in the art of pharmacy for administration in any suitable manner, for example orally, parenterally (including subcutaneously, intramuscularly or intravenously), or topically, the mode  
20 of administration, type of preparations or formulation and the dosage being generally determined by the details of the associated cytotoxic drug chemotherapy or radiotherapy that is to be enhanced.

25 In making up such pharmaceutical formulations in the form of sterile liquid preparations for parental use for instance, a predetermined therapeutically effective non-toxic amount of the particular compound concerned may be dissolved in phosphate buffered saline and the  
30 preparations may be presented in unit dosage form and contained in sealed ampoules ready for use. In general, at least in aqueous solution, concentrations not greater than 200mg/ml will be preferred, but the amount and dosage routine required for optimum effectiveness will of  
35 course vary and is ultimately at the discretion of the medical or veterinary practitioner treating the mammal concerned in each particular case. Where the compound is to be used in conjunction with a cytotoxic drug, the latter in some cases may be administered simultaneously

and may be conveniently incorporated in the same pharmaceutical formulation or composition.

As indicated, the compounds according to this  
5 invention have at least potential as PARP inhibitors, and  
in vitro tests hereinafter described have demonstrated  
positive pharmacological activity which it is believed  
reflects the activity to be found in vivo in the course  
of therapeutic clinical use.

10

It will be understood that where reference is made  
in this specification to compounds of formula I such  
reference should be construed as extending also to their  
pharmaceutically acceptable salts and to other  
15 pharmaceutically acceptable bioprecursors (pro-drug  
forms) where relevant. The term "pro-drug" is used in  
the present specification to denote modified forms or  
derivatives of a pharmacologically active compound which  
biodegrade *in vivo* and become converted into said active  
20 compound after administration, especially oral or  
intravenous administration, in the course of therapeutic  
treatment of a mammal. Such pro-drugs are commonly  
chosen because of an enhanced solubility in aqueous  
media which helps to overcome formulation problems, and  
25 also in some cases to give a relatively slow or  
controlled release of the active agent.

A satisfactory pro-drug must generally be a water-soluble derivative which is non-toxic and reasonably  
30 stable in solution at physiological pH but which will biodegrade or convert, e.g. by enzymatic degradation or by an environmental pH change, to the active compound at the location required following administration in the course of therapy. For the benzimidazole compounds of  
35 the present invention, pro-drug forms may conveniently be provided by carbamate or amino acid derivatives, e.g. glycine or other amino-acid carbamate derivatives, or by phosphate derivatives. Phosphate derivatives may be susceptible to enzymic dephosphorylation *in vivo* and are

presently preferred, especially water-soluble ammonium or alkali metal phosphate salts. These may often be conveniently prepared from compounds of structural formula I having at least one hydroxyl group substituent,  
5 e.g. in an aromatic ring component of R, by reacting with a dibenzyl phosphonate, preferably in the presence of a tertiary base such as *N,N*-diisopropylethylamine.

In cases where R is phenyl (or benzyl) and where it  
10 is necessary to have a substituent other than hydroxyl, e.g. NO<sub>2</sub>, CO<sub>2</sub>H, CN etc. at the 4' position in order to give satisfactory PARP inhibitory activity, a hydroxyl substituent amenable to phosphorylation or other pro-drug modification may be provided at another aromatic ring  
15 position, e.g. at the 3' position.

In all the water-soluble pro-drug forms presently envisaged the phosphate, carbamate or other water-solubilizing pro-drug moiety will be a component of R or  
20 R' in structural formula I.

It should also be understood that where any of the compounds referred to can exist in more than one enantiomeric form, all such forms, mixtures thereof, and  
25 their preparation and uses are within the scope of the invention.

DESCRIPTION OF EXAMPLES OF PREFERRED EMBODIMENTS

The following examples and descriptions of stages in synthetic routes of preparation of various preferred compounds of interest serve to further illustrate the present invention, but should not be construed in any way as a limitation thereof.

In the first example (EXAMPLE 1), the preparation is described of various intermediate compounds required for the preparation of benzimidazole compounds in accordance with the present invention which are described in EXAMPLES 2 to 6.

15

EXAMPLE 1Preparation of Intermediate Compounds20    (a) 3-Nitrophthalamic acid

3-Nitrophthalic anhydride (10.0g, 50 mmol) was added in portions over 20 minutes to concentrated aqueous ammonia solution (15ml), and the mixture was stirred at 30°C for a further 30 minutes. The crystalline mass of ammonium phthalamate, deposited upon cooling the pale yellow solution, was collected and redissolved in a minimum amount of warm water. Concentrated hydrochloric acid (4.5ml) was added dropwise, with stirring, and the resulting paste was washed with water, and dried *in vacuo* to give 3-nitrophthalamic acid as a fine white powder. (9.01g, 83%), m.p. 217°C

Found: C, 45.76; H, 2.79; N, 13.21.

$C_8H_6N_2O_5$  requires C, 45.71; H, 2.86; N, 13.33%;  $\nu_{max}/cm^{-1}$  3466.52, 3321.84, 1668.64, 1604.98, and 1525.89;  $\delta_H$  ( $d_6$ -DMSO, 200 MHz) 7.75 (1H, br s, CONH), 7.8 (1H, t, Ar-5H), 8.16 (1H, brs, CONH), 8.2 (1H, d, Ar-6H), 8.3 (1H, d, Ar-4H);  $\delta_C$  ( $d_6$ -DMSO) 127.32, 130.06, 132.28, 133.49, 134.78, 147.71, 166.25, and 166.60;  $m/z$  (EI) 192 ( $M^+-1$ ), 177, 149, 103, 75.

(b) 2-Amino-3-nitrobenzoic acid (3-nitroanthranilic acid)

To a stirred solution of potassium hydroxide 5 (24.1g) in water (110ml) at 0°C was added bromine (2.46ml), followed by 3-nitrophthalamic acid 10g, 47.62mmol). The reaction mixture was stirred for 3 hours at 60°C, cooled to room temperature, and stirred for a further 12 hours. The orange precipitate was collected, 10 redissolved in a minimum amount of water, and acidified by the dropwise addition of concentrated hydrochloric acid. Recrystallisation of the resulting yellow solid from hot water afforded 3-nitroanthranilic acid as yellow microcrystals (6.42g, 74%), m.p. 208-209°C

15 Found: C, 45.83; H, 3.07; N, 15.21.

$C_7H_6N_2O_4$  requires C, 46.15; H, 3.29; N, 15.38%;  $\nu_{max}/cm^{-1}$  3476.17, 3344.99, 3094.21 and 1687.93;  $\delta_H$  ( $d_6$ -DMSO, 200MHz) 6.76-6.84 (1H, t, Ar-5H), 8.29-8.41 (2H, dd, Ar-4/6H), 8.60 (2H, s, Ar-NH<sub>2</sub>), 13.4-14.0 (1H, br s, Ar-CO<sub>2</sub>H);  $\delta_C$  ( $d_6$ -DMSO) 113.19, 131.97, 140.02 (Ar-4/5/6CH), 20 CO<sub>2</sub>H; 115.02 (Ar-C-NH<sub>2</sub>), 132.77 (Ar-C-CO<sub>2</sub>H), 147.09 (Ar-C-NO<sub>2</sub>), 168.95 (Ar-CO<sub>2</sub>H); *m/z* (EI) 182 (M<sup>+</sup>), 164.

(c) Methyl 2-amino-3-nitrobenzoate

25

Hydrogen chloride gas was bubbled through a solution of 2-amino-3-nitrobenzoic acid (0.5g, 2.75 mmol) in methanol (40ml) for 15 minutes at 0°C. The reaction mixture was heated under reflux for 5 hours, and allowed 30 to cool to room temperature over a further 12 hours, whereupon methyl 2-amino-3-nitrobenzoate was deposited as a yellow solid (417mg, 77%), m.p. 95-96°C

Found: C, 49.09; H, 3.78; N, 14.03.

$C_8H_8N_2O_4$  requires C, 48.98; H, 4.08; N, 14.29%;  $\nu_{max}/cm^{-1}$  3452.5, 3316.9, 1702, and 1253.7;  $\delta_H$  ( $d_6$ -DMSO, 200 MHz) 3.95 (3H, s, OCHH<sub>3</sub>), 6.79-6.87 (1H, t, Ar-5H), 8.28-8.33 (1H, dd, Ar-4H), 8.41-8.46 (1H, dd, Ar-6H), 8.45-8.46 (2H, br s, Ar-NH<sub>2</sub>); *m/z* (EI) 196 (M<sup>+</sup>), 164, 118, 90, 63.

(d) 2,3-Diaminobenzoic Acid

Palladium on carbon catalyst (10% Pd, ~200mg) was added cautiously, as a slurry in methanol (10ml), to a solution of 3-nitroanthranilic acid (2.44g, 13 mmol) in methanol (120ml), and the mixture was stirred under a hydrogen atmosphere for 2 hours until the absorption of gas ceased. The catalyst was removed by filtration through Celite, and the filtrate was evaporated to dryness under reduced pressure to afford the crude product. Purification by column chromatography on silica gel, with dichloromethane:methanol (4:1) as eluent, gave 2,3-diaminobenzoic acid as a red solid (1.34g, 66%).

15  $\nu_{\text{max}}$ /cm<sup>-1</sup> 3433.73, 2882.02, 2602.30 and 1658.99;  $\delta_{\text{H}}$  ( $d_6$ -DMSO, 200 MHz) 5.8-7.4 (4H, br s, 2 x NH<sub>2</sub>), 6.45 (1H, t, Ar-5H), 6.75 (1H, d, Ar-4H), 7.20 (1H, d, Ar-6H);  $\delta_{\text{C}}$  ( $d_6$ -DMSO) 110.31, 115.45, 118.33, 120.55, 135.03, 140.36, 170.68; m/z (EI) 152 (M<sup>+</sup>), 134, 106, 79.

20

(e) Methyl 2,3-diaminobenzoate

A solution of 2,3-diaminobenzoic acid (0.2g, 1.32 mmol) in methanol (40ml) was saturated with hydrogen chloride as described above, and the mixture was subsequently heated under reflux for 2 hours. The solid residue obtained on evaporation of the solvent was dissolved in water, and the solution was adjusted to pH 7.0 with sodium hydrogen carbonate. After extraction 25 with ethyl acetate (2 x 30ml), the combined organic layers were dried (MgSO<sub>4</sub>), and the solvent was removed to give methyl 2,3-diaminobenzoate as a brown oil which solidified on trituration with petrol (40/60) (121.6mg, 56%), m.p. 62-63°C

30 35 Found: C, 58.35; H, 5.80; N, 16.69.  
C<sub>8</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub> requires C, 57.83; H, 6.02; N, 16.87%;  $\delta_{\text{H}}$  ( $d_6$ -DMSO), 200MHz) 3.87 (3H, s, OCH<sub>3</sub>), 4.90 (2H, br s, Ar-2-NH<sub>2</sub>), 6.32 (2H, br s, Ar-3-NH<sub>2</sub>), 6.46-6.54 (1H, t, Ar-5H), 6.80-6.84 (1H, dd, Ar-4H), 7.18-7.23 (1H, dd, Ar-

6H); m/z (EI) 166 (M<sup>+</sup>), 134, 106, 79.

Methyl 2,3-diaminobenzoate was also prepared by reduction of methyl 2-amino-3-nitrobenzoate as follows: a 5 solution of methyl 2-amino-3-nitrobenzoate (284mg, 1.45 mmol) in methanol (40ml), containing palladium on carbon catalyst (10% Pd, ~50mg), was stirred under hydrogen for 24 hours. The solution was filtered through Celite to remove the catalyst, and the solvent was evaporated in 10 vacuo to afford the methyl ester as a brown solid. (180mg, 75%) identical to methyl 2,3-diaminobenzoate prepared above.

(f) Methyl 2-amino-3-N-benzoylaminobenzoate

15

A solution of benzoyl chloride (38.4 µl, 0.331 mmol) in tetrahydrofuran (5ml) was added dropwise to a solution of methyl 2,3-diaminobenzoate (50mg, 0.301 mmol) in dry tetrahydrofuran (5ml), containing triethylamine 20 (46 µl) and 4-dimethylaminopyridine (1.8mg, 5 mol %). After stirring the mixture for 24 hours at 45°C, solvents were evaporated, and the crude product was purified by column chromatography on silica gel, with petrol (40/60); ethyl acetate (3:2) as eluent. Recrystallisation from 25 ethyl acetate-petrol (40/60), gave the title compound as white crystals. (60mg, 74%); δ<sub>H</sub> (d<sub>6</sub>-DMSO, 200MHz) 3.95 (3H, s, OCH<sub>3</sub>), 6.64 (2H, br s, Ar-NH<sub>2</sub>), 6.69-6.77 (1H, t, Ar-5H), 7.46-7.50 (1H, d, Ar-4H), 7.59-7.70 (3H, m, Ph-3 and Ph-3' 4H), 7.81-7.85 (1H, d, Ar-6H), 8.11-8.14 (2H, 30 d, Ph-2H and Ph-2'H), 9.8-9.9 (1H, br, s, Ar-NHCO); m/z (EI) 270 (M<sup>+</sup>), 253, 105.

(g) Methyl 2-amino-3-N-(4'-methoxybenzoyl)aminobenzoate

35 To a solution of methyl 2,3-diaminobenzoate (460mg, 2.77 mmol) in dry tetrahydrofuran (20ml) was added 4-methoxybenzoyl chloride (378 µl, 2.77 mmol), triethylamine (385.5 µl, 2.77 mmol), and 4-dimethylaminopyridine (17mg, 5 mol%). The reaction mixture was stirred at room

temperature overnight, yielding an insoluble precipitate that was collected by filtration. The filtrate was evaporated under reduced pressure and the residual solid was redissolved in boiling methanol, and hot filtered to remove the insoluble material. The solvent was removed *in vacuo*, and the solid residue was combined with the previously collected precipitate. Recrystallisation from aqueous methanol afforded white crystals of the title compound. (513.2mg, 62%); mp 179-180°C;

Found: C, 64.26; H, 5.31; N, 9.17.

$C_{16}H_{16}N_2O_4$  requires C, 64.0; H, 5.33; N, 9.33;  $\nu_{max}/cm^{-1}$  3425.54, 3341.54, 3277.84, 1699.24, 1632.12, 1251.11;  $\delta_H$  ( $d_6$ DMSO, 200MHz) 3.92 (3H, s, OMe), 3.94 (3H, s, OMe), 6.59 (2H, s, Ar-NH<sub>2</sub>), 6.68-6.75 (1H, t, Ar-5H), 7.13-7.17 (2H, d,  $J=8.8$ , Ph-3/3'H), 7.43-7.46 (1H, d, Ar-4H), 7.79-7.83 (1H, d, Ar-6H), 8.07-8.12 (2H, d,  $J=8.8$ , Ph-3.3'H), 9.7 (1H, br s, -NHCO-);  $\delta_C$  ( $d_6$ DMSO) 51.98, 55.76, 110.62, 113.79, 114.67, 125.0, 126.84, 129.12, 130.14, 133.20, 147.36, 162.21, 165.74, 168.33;  $m/z$  (EI) 300 (M+), 135, 107, 77.

(h) Methyl 2-phenylbenzimidazole-4-carboxylate

A solution of methyl 2-amino-3-N-benzoylaminobenzoate (6.3mg, 0.023 mmol) in glacial acetic acid (0.5ml) was stirred under reflux for 15 minutes. After cooling, the solvent was removed under reduced pressure to afford the title compound;  $\delta_H$  ( $d_6$ -DMSO, 200 MHz) 4.09 (3H, s, OCH<sub>3</sub>), 7.40-7.48 (1H, t, Ar-5H), 7.64-7.70 (3H, m, 2-Ph-3H and 3'-Ph-4H), 7.93-7.97 (1H, d, Ar-4H), 8.06-8.10 (1H, d, Ar-6H), 8.39-8.41 (2H, d, 2-Ph-2/2'H), 12.4-12.5 (1H, br, s, Ar-NHCO).

EXAMPLE 2Benzimidazole-4-carboxamide (Compound NU1066)5    (a) 1st Stage - Preparation of Benzimidazole-4-carboxylic acid (Compound NU1067)

A mixture of 2,3-diaminobenzoic acid (0.5g, 3.29 mmol) and formic acid (405  $\mu$ l, 9.87 mmol) in hydrochloric acid (4M, 10ml) was heated under reflux for one hour. The precipitate which formed on cooling was collected, redissolved in boiling methanol, and decolorised with activated charcoal. Evaporation of the solvent gave benzoxazole-4-carboxylic acid as a white powder (407.9mg, 15 77%)

Found: C, 46.11; H, 3.63; N, 13.27.

$C_8H_6N_2O_2 \cdot HCl \cdot 0.5 H_2O$  requires C, 46.28; H, 3.88; N, 13.49%;

$\delta_H$ ( $d_6$ -DMSO, 200 MHz) 7.7-7.8 (1H, t, Ar-5H), 8.2-8.3 (2H, 20 dd, Ar-4/6H), 9.65 (1H, s, imidazole-2H).

(b) 2nd Stage - Preparation of Benzimidazole-4-carboxamide (Compound NU1066)

25    A suspension of benzimidazole-4-carboxylic acid (3.97.4 mg, 2.45 mmol) in thionyl chloride (10ml) was heated under reflux for 3.5 hours, and the thionyl chloride was removed by vacuum distillation. The residual solid was suspended in dry tetrahydrofuran (10ml) and added dropwise to concentrated aqueous ammonia (50ml) with stirring over 30 minutes. Excess solvent was removed *in vacuo*, and the residue was dissolved in a minimum volume of water and extracted with ethyl acetate (2 x 20ml). The solid recovered on evaporation of the 30 combined organic layers was dissolved in hydrochloric acid (0.1M, 10ml) and the insoluble precipitate was removed by filtration. The aqueous filtrate was carefully adjusted to pH 9 in increments of 1 pH unit, and ethyl acetate extractions (10ml) were undertaken at 35

each step. The combined extracts were dried ( $MgSO_4$ ) and the solvent was evaporated. Recrystallisation from ethyl acetate furnished benzimidazole-4-carboxamide (50mg, 13%)

5 Found: C, 59.95; H, 3.90; N, 24.59.  
 $C_9H_7N_3O$  requires C, 59.63; H, 4.35; N, 26.09%;  
uv/nm 210, 270, 291;  $\nu_{max}/cm^{-1}$  3321.84, 3150.16, 1747.73,  
1680.21;  $\delta_H$  ( $d_6$ -DMSO, 200 MHz) 7.4 (1H, t, Ar-5H), 7.8-  
8.0 (3H, dd, Ar-4/6H), 8.5 (1H, br s, imidazole-2H), 9.4  
10 (1H, br s, CONH), 13.1 (1H, br s, CONH);  $m/z$  (EI) 161  
(M $^+$ ), 141, 116, 99.

### EXAMPLE 3

15 2-Methylbenzimidazole-4-carboxamide (Compound NU1064)

(a) 1st stage - Preparation of 2-Methylbenzimidazole-4-carboxylic acid

Acetic acid (0.23ml) was added to a solution of  
20 2,3-diaminobenzoic acid (200mg, 1.32 mmol) in hydrochloric acid (4M, 3.2ml) and the mixture was refluxed for 1 hour. Solvents were evaporated and the residual solid was redissolved in boiling methanol (5ml) and decolorised with activated charcoal. Removal of the  
25 solvent furnished 2-methylbenzimidazole-4-carboxylic acid as an amorphous white solid (167.5mg, 72%);  $\delta_H$  ( $d_6$ -DMSO) 2.9 (3H, s, imidazole-2-CH $_3$ ), 7.6-7.8 (1H, t, Ar-5H) 8.1 (2H, d, Ar-4/6H);  $m/z$  (EI 176 (M $^+$ ), 158, 130.

30

(b) 2nd stage - Preparation of 2-Methylbenzimidazole-4-carboxamide (Compound NU1064)

A suspension of 2-methylbenzimidazole-4-carboxylic acid (500mg, 2.84 mmol) in thionyl chloride (10ml) was heated under reflux for 2 hours, and the thionyl chloride was removed by vacuum distillation. The solid residue was redissolved in dry tetrahydrofuran, and added dropwise to concentrated aqueous ammonia solution (50ml)

over 30 minutes, with stirring. The solvent was removed under vacuum, and the solid residue was redissolved in a minimum of hot water, filtered, and extracted with ethyl acetate (2 x 30ml). Evaporation of the solvent afforded 5 a brown solid which was recrystallised from ethyl acetate to give the title compound as a white solid (70.1mg, 14%)

Found: C, 61.47; H, 4.96; N, 23.39.

C<sub>9</sub>H<sub>9</sub>N<sub>3</sub>O requires C, 61.71; H, 5.14; N, 24.0%;  
10 uv/nm 209, 270;  $\nu_{max}/cm^{-1}$  3296.77, 3071.07, 1913.63,  
1859.62, 1805.60;  $\delta_H$  (d<sub>6</sub>-DMSO, 200 MHz) 2.68 (3H, s,  
imidazole-2-CH<sub>3</sub>), 7.30-7.38 (1H, t, Ar-5H), 7.72--7.46  
(1H, d, Ar-4H), 7.86-7.90 (1H, d, Ar-6H), 7.72-7.90 (1H,  
br s, imidazole-NH), 9.4 (1H, br s, CONH), 12.8 (1H, brs,  
15 CONH); m/z (EI) 175 (M<sup>+</sup>), 158, 130.

#### EXAMPLE 4

##### 2-Phenylbenzimidazole-4-carboxamide (Compound NU1070)

20 (a) 1st Stage - Preparation of 2-phenylbenzimidazole-4-carboxylic acid  
A mixture of 2,3-diaminobenzoic acid (0.1g, 0.66 mmol), benzoic acid (80.2mg, 0.66 mmol) and 25 polyphosphoric acid (~5ml) was heated at 150-160°C for 30 minutes, and, after cooling, crushed ice (~10g) was added. Insoluble materials were removed from the dark solution by filtration, and the filtrate was extracted with ethyl acetate (2 x 20ml) to remove unreacted benzoic acid. The aqueous solution was cautiously neutralised 30 with sodium hydroxide (10 M), filtered, and the filtrate was extracted with ethyl acetate (2 x 30ml). The combined extracts were dried (MgSO<sub>4</sub>) and the solvent was evaporated. Chromatography on silica gel, with 35 dichloromethane:methanol (85:15) as eluent, gave the title compound (31.2mg, 20%);  $\delta_H$  (d<sub>6</sub>-DMSO, 200 MHz) 7.4 (1H, t, Ar-5H), 7.62 (3H, br s, 3-Ph-4H and 3'-Ph-4H), 7.91 (1H, d, Ar-6H), 7.97 (1H, d, Ar-4H), 8.39 (2H, d, Ph-2H and Ph2'-H); m/z (EI) 238 (M<sup>+</sup>), 220, 192, 77.

(b) 2nd Stage - Preparation of 2-phenylbenzimidazole-4-carboxamide (NU1070)

2-Phenylbenzimidazole-4-carboxylic acid (50mg, 0.21 mmol) was dissolved in dry tetrahydrofuran (10ml) and 5 thionyl chloride (16.8  $\mu$ l, 0.231 mmol) and DMF (0.05ml) were added. The mixture was stirred at room temperature for 12 hours, when a white precipitate developed, and the suspension was added dropwise to stirred aqueous ammonia (10ml) over 10 minutes. The mixture was stirred for a 10 further 30 minutes, diluted with water (20ml), and neutralised with hydrochloric acid (4M). The white solid which was precipitated upon cooling, was collected by filtration to afford 2-phenylbenzimidazole-4-carboxamide (31mg, 62%);  $\nu_{\text{max}}/\text{cm}^{-1}$  3320, 3180, 1660 and 1600;  $\delta_{\text{H}}$  ( $d_6$ -DMSO, 200 MHz) 7.45 (1H, t, Ar-5H), 7.72 (3H, d, 3-Ph-4H), 7.87 (1H, d, Ar-4H), 7.97 (1H, br s, CONH), 7.99 (2H, d, Ar-6H), 8.38 (2H, d, Ph-2-H and Ph-2-H), 9.5 (1H, br s, CONH);  $m/z$  (EI) 237 ( $M^+$ ), 220, 192, 165, 77.

20

EXAMPLE 5

2-(4'-Methoxyphenyl)benzimidazole-4-carboxamide (NU1076)

25 (a) 1st Stage - Preparation of Methyl 2-(4'-methoxy-phenyl)benzimidazole-4-carboxylate Acetate Salt

Methyl 2-amino-3-N-(4'-methoxybenzoyl)benzoate (480mg, 1.6 mmol) was dissolved in glacial acetic acid (15ml), and heated at 120°-130°C for 30 minutes. The 30 solvent was removed and the solid residue was recrystallised from ethyl acetate-petrol (40/60) to yield the product as a white crystalline solid. (409mg, 75%); mp 141-142°C;

Found: C, 63.68; H, 4.79; N, 7.88;

35  $C_{16}H_{14}N_2O_3 \cdot CH_3CO_2H$  requires C, 63.16; H, 5.26; N, 8.19;  $\nu_{\text{max}}/\text{cm}^{-1}$  3375.33, 1718.46, 1696.80, 1282.81, 1257.81, 1257.34;  $\delta_{\text{H}}$  ( $d_6$ -DMSO), 200MHz) 2.02 (3H, s,  $CH_3CO_2H$ ), 3.97 (3H, s, OMe), 4.09 (3H, s, OMe), 7.21-7.25 (2H, d,  $J=8.6$ , Ph-3/3'H), 7.39-7.46 (1H, t, Ar-5H), 7.90-7.93 (1H, d,

Ar-4H), 8.00-8.04 (1H, d, Ar-6H), 8.36-8.40 (2H, d, J=8.6, Ph-2/2'H), 12.1 (1H, s, Imz-H), 12.3-12.4 (1H, br, s, CH<sub>3</sub>CO<sub>2</sub>H); δ<sub>C</sub> (d<sub>6</sub>DMSO) 21.35, 52.37, 55.64, 114.41, 121.68, 122.35, 124.34, 129.56, 153.63, 161.27, 166.13, 5 172.37; m/z (EI) 282 (M<sup>+</sup>-CH<sub>3</sub>CO<sub>2</sub>H), 250, 222, 77, 60, 43, 32.

(b) 2nd Stage - Preparation of 2-(4'-Methoxyphenyl)benzimidazole-4-carboxamide (NU1076)

10 The acetate salt of methyl (2-(4'-methoxyphenyl)benzimidazole-4-carboxylate was dissolved in excess liquid ammonia and heated at 100°C in a sealed pressure vessel at 40 atmospheres overnight. The ammonia was allowed to evaporate, and the solid residue was 15 collected and washed with ice cold water (3 x 5ml). Recrystallisation from aqueous methanol afforded the title compound (226.4mg, 80%); mp 261-263°C; Found: C, 66.07; H, 4.23; N, 15.29.  
C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>. 0.2CH<sub>3</sub>OH requires C, 66.70; H, 5.08; N, 20 15.35;  
ν<sub>max</sub>/cm<sup>-1</sup> 3321.47, 3140.72, 1656.23, 1608.25, 1421.43, 1242.55; δ<sub>H</sub> (d<sub>6</sub>DMSO, 200MHz) 3.96 (3H, s, OMe), 7.23-7.27 (2H, d, J=8.6, Ph-3/3'H), 7.37-7.45 (1H, t, Ar-5H), 7.78-7.82 (1H, d, Ar-4H), 7.87 (1H, br s, Imz-H), 7.93-7.96 25 (1H, d, Ar-6H), 8.27-8.31 (2H, d, J=8.6, Ph-2/2'H), 9.4-9.5 (1H, br s, -CONH), 13.3-13.4 (1H, br s, -CONH); m/z (EI) 267 (M<sup>+</sup>), 249, 222, 206, 77, 32.

EXAMPLE 6

30 2-(4'-trifluoromethyl)benzimidazole-4-carboxamide (NU1077)

(a) 1st Stage - Preparation of Methyl 2-amino-3-N-(4'-trifluoromethylbenzoyl)aminobenzoate

To a solution of methyl 2,3-diaminobenzoate (300mg, 1.807 mmol) was added 4-trifluoromethylbenzoyl chloride (268.4 μl, 1.807 mmol), triethylamine (251.4 μl, 1.807 mmol) and 4-dimethylaminopyridine (11mg, 5mol%), and the

mixture was stirred at room temperature overnight. The reaction solvent was removed under reduced pressure and the resulting solid was washed with ethyl acetate. Recrystallisation twice from methanol-water gave the title compound as a white solid. (83.6mg, 14%); mp 180-181°C;

Found: C, 56.75; H, 3.50; N, 8.28.

$C_{16}H_{13}F_3N_2O_3$  requires C, 56.80; H, 3.85; N, 8.28; uv/nm 222;  $\delta_H$  ( $d_6$ -DMSO, 200MHz) 3.93 (3H, s, OMe), 6.70-6.76 (3H, m, Ar-5H, Ar-NH<sub>2</sub>), 7.46-7.49 (1H, d, Ar-4H), 7.81-7.85 (1H, d, Ar-6H), 7.99-8.03 (2H, d), 8.29-8.33 (2H, d), 10.05 (1H, s, -NHCO-); m/z (EI) 338 (M<sup>+</sup>), 321, 289, 145, 32.

15 (b) 2nd Stage - Preparation of Methyl 2-(4'-trifluoro-methylphenyl)benzimidazole-4-carboxylate Acetate Salt

Methyl 2-amino-3-N-(4'-trifluoromethylbenzoyl)aminobenzoate (75.7mg, 0.224 mmol) was dissolved in glacial acetic acid (5ml) and stirred at 125°C for 0.5 hour. The solvent was evaporated and the remaining white solid was washed with petrol (40/60) to yield the title compound. (59.6mg, 70%); mp 138-140°C;

Found: C, 56.78; H, 3.98; N, 7.36;

25  $C_{16}H_{11}F_3N_2O_2CH_3CO_2H$  requires C, 56.84; H, 3.94; N, 7.37. uv/nm 206, 319;  $\delta_H$  ( $d_6$ -DMSO, 200MHz) 2.01 (3H, s, CH<sub>3</sub>CO<sub>2</sub>H), 7.44-7.52 (1H, t, Ar-5H), 7.97-8.14 (4H, m), 8.65-8.66 (2H, d), 12.1 (br s, Imidazole-NH), 12.7-12.8 (1H, br s, CH<sub>3</sub>CO<sub>2</sub>H); m/z (EI) 320 (M<sup>+</sup>-CH<sub>3</sub>CO<sub>2</sub>H), 301, 288, 260, 145, 60, 43.

(c) 3rd Stage - Preparation of 2-(4'-trifluoromethyl)benzimidazole-4-carboxamide (NU1077)

The acetate salt of methyl 2-(4'-trifluoro-methylphenyl)benzimidazole-4-carboxylate was dissolved in excess liquid ammonia and heated at 100°C, in a sealed pressure vessel at 40 atmospheres, for 12 hours. The ammonia was allowed to evaporate, and the solid residue was washed with ice cold water (3 x 5ml).

Recrystallisation from methanol-water yielded the product as fine white needles. (19.1mg, 48%); mp 301-305°C; Found: C, 56.45; H, 3.50; N, 12.41.

C<sub>15</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O.CH<sub>3</sub>OH requires C, 56.97; H, 4.18; N, 12.46;  
5 δ<sub>H</sub> (d<sub>6</sub>-DMSO, 200MHz) 7.45 (1H, t, Ar-5H), 7.88-7.92 (1H, d, Ar-4H), 7.99 (1H, br s imidazole-NH), 8.03 (1H, d, Ar-6H); 8.06-8.10 (2H, d, J=8.1), 8.55-8.59 (2H, d, J=8.1), 9.3-9.4 (1H, br s, -CONH), 13.7-13.8 (1H, br s, -CONH); m/z (EI) 288 (M<sup>+</sup>-NH<sub>3</sub>), 260, 69.

10

EXAMPLE 7

2-(4'-Hydroxyphenyl)-1-H-benzimidazole-4-carboxamide  
15 (Compound NU1085)

Under an argon atmosphere 1M boron tribromide in dichloromethane (3.8ml, 3.79 mmol) was transferred to a flask containing 2-(4'-methoxyphenyl)benzimidazole-4-carboxamide (NU 1076 from Example 5) (202.4mg, 0.758 mmol). The resulting solution was refluxed for 24 hours using an air condenser. The solvent was removed by distillation to complete dryness. The solid residue was treated with 10% NaOH (10ml), followed by dropwise addition of concentrated hydrochloric acid to neutralise (pH 7). The white precipitate was collected by filtration and dissolved in ethyl acetate (10ml). The organic solvent was washed with water (2 x 3ml), dried over MgSO<sub>4</sub>, and the product was obtained by removal of the solvent under reduced pressure. (109.5mg, 57%). mp 266-267°C;

Found C 63.27, H 4.37, N 15.67 C<sub>14</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>.0.75 MeOH requires C 63.04 H 4.69 N 15.76; ν<sub>max</sub>(cm<sup>-1</sup>) 3424.01, 3384.16, 3309.20, 3249.55, 3155.62, 1642.35, 1618.02, 1594.50, 1577.74; δ<sub>H</sub> 7.03-7.07 (2H, d, J=8.5), 7.34-7.42 (1H, t), 7.75-7.79 (1H, d), 7.85 (1H, br s), 7.90-7.94 (1H, d), 8.15-8.19 (2H, d, J=8.5), 9.4-9.6 (1H, br s), 10.0-10.4 (1H, br s), 13.0-13.4 (1H, br s); m/z (EI) 253 (M<sup>+</sup>), 236, 208, 93.

EXAMPLE 82-(4'-Methoxyphenyl)-1-methylbenzimidazole-4-carboxamide  
(Compound NU1090)

5

2-(4'-Methoxyphenyl)benzimidazole-4-carboxamide (NU1076 from Example 5) (105.3mg, 0.394 mmol) and powdered potassium hydroxide (22mg, 0.394 mmol) were suspended in acetone (4ml) and stirred until all the 10 solids had dissolved. Methyl iodide (24.6 $\mu$ l, 0.394 mmol) was added and the reaction stirred at room temperature overnight. The solvent was removed under reduced pressure and the white solid residue purified by column chromatography with dichloromethane/methanol 95:5 15 to give fine white crystals of the title compound. (33.2mg, 30%)

mp 289-292°C; Found C 68.62 H 5.36 N 14.67 C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub> Requires C 68.33 H 5.34 N 14.95;  $\nu_{max}$ (cm<sup>-1</sup>) 3309.23, 3141.44, 1671.29, 1605.30, 1255.08,  $\delta_H$  3.95 (3H, s), 4.02 (3H, s), 7.22-7.27 (2H, d), 7.44-7.52 (1H, t), 7.86-8.00 (5H, m), 9.4 (1H, br s, NH);  $m/z$  (EI) 281 (M<sup>+</sup>), 264, 250.

25 EXAMPLE 92-(4'-Methoxyphenyl)-1-benzoylbenzimidazole-4-carboxamide  
(Compound NU1101)

30 A solution of 2-(4'-Methoxyphenyl)benzimidazole-4-carboxamide (NU1076 from Example 5) (75.1mg, 0.281 mmol) and powdered potassium hydroxide (15.8mg, 0.281 mmol) was prepared in acetone (3ml) and stirred until all the 35 solids had dissolved. Benzoyl chloride (32.6  $\mu$ l, 0.281 mmol) was added and the solution stirred overnight at room temperature, with the production of a white precipitate. The solvents were removed under reduced pressure, and the white residue was purified by column chromatography using dichloromethane/methanol 95:5. The

resulting solid was recrystallised from petrol 40/60 / ethyl acetate to give the pure product as brilliant white prisms. (15.6mg, 15%).

mp 207-210°C; Found C 70.45 H 4.60 N 10.99  
5 C<sub>22</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>.0.25 CH<sub>3</sub>OH Requires C 70.45 H 4.47 N 11.08  
 $\nu_{\text{max}}(\text{cm}^{-1})$  3445.99, 3318.55, 2922.99, 1689.79, 1666.36;  
 $\delta_{\text{H}}$  3.86 (3H, s, OCH<sub>3</sub>), 7.02-7.06 (2H, d), 7.50-7.65 (4H,  
m), 7.72-7.82 (3H, m), 7.88-7.92 (2H, d), 8.08 (1H, s,  
CONH), 8.10-8.14 (1H, d), 9.1-9.2 (1H, br s, CONH); *m/z*  
10 (EI) 371 (M<sup>+</sup>), 105.

#### FURTHER EXAMPLES

15 The following further examples, and also some of  
the examples already described, make use of certain  
common standard procedures. These comprise:

(1) Reaction of Methyl 2,3-diaminobenzoate with Aryl  
20 Acid Chlorides (Standard Procedure A)

(2) Benzimidazole Ring Formation by Acid Catalysed  
Cyclisation (Standard Procedure B)

25 (3) Amide Formation by Reaction with Liquid Ammonia  
(Standard Procedure C)

The experimental details of these standard  
procedures are described below:

30

#### Standard Procedure A

An ice/salt bath cooled solution of methyl 2,3-diaminobenzoate (1 equivalent), dry triethylamine (1-1.5  
35 equivalents) and dimethylaminopyridine (DMAP - 5mol%) in half the required volume of dry tetrahydrofuran (THF) was prepared. The required acid chloride (1 equivalent) was dissolved in the remaining dry tetrahydrofuran (THF) and added to the cooled solution with stirring over 30

minutes. The reaction was allowed to warm slowly to room temperature and was stirred overnight. The solvent was filtered to remove a precipitate which was suspended in ethyl acetate, washed twice with water followed by 5 saturated brine, and dried with MgSO<sub>4</sub>. The organic layer was added to the reaction filtrate, and the solvent removed under reduced pressure. The solid residue was redissolved in ethyl acetate, washed twice with water followed by saturated brine, and dried with MgSO<sub>4</sub>. 10 Removal of the solvents under reduced pressure left a solid residue which was purified by column chromatography and/or recrystallisation from suitable solvents.

15 Standard Procedure B

The starting material was dissolved in glacial acetic acid and plunged into a pre-heated oil bath at 120°C. The solution was heated for the appropriate time 20 and then allowed to cool to room temperature. The acetic acid was removed under reduced pressure and the solid residue purified by column chromatography and/or recrystallisation from suitable solvents.

25

Standard Procedure C

The starting material was dissolved in a excess of freshly condensed liquid ammonia. This was heated to 30 80°C within a sealed vessel, generating a pressure of 40 atmospheres, for 24 hours. The ammonia was evaporated, and the solid residue obtained purified by column chromatography and/or recrystallisation from suitable solvents.

35

EXAMPLE 102-(4'-Cyanophenyl)-1-H-benzimidazole-4-carboxamide  
(NU1092)

5

(a) 1st Stage - Preparation of Methyl 2-amino-3-N-(4'-cyanobenzoyl)aminobenzoate

Following standard procedure A, methyl 2,3-diaminobenzoate (300mg, 1.81 mmol), triethylamine (251 10  $\mu$ l, 1.81 mmol) and DMAP (11mg) were dissolved in THF (7.5ml) and cooled. To this was added 4-cyanobenzoyl chloride (299mg, 1.81 mmol) dissolved in THF (7.5ml). The product was purified by column chromatography, dichloromethane/methanol 99:1, followed by 15 recrystallisation from boiling methanol. (196mg, 37%)  
mp 198-202°C;  $\nu_{\text{max}}$ (cm<sup>-1</sup>) 3486.40, 3374.02, 3245.61, 2231.25, 1688.04, 1646.65;  $\delta_{\text{H}}$  3.93 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 6.68-6.76 (1H, t), 6.72 (2H, br s, NH<sub>2</sub>), 7.45-7.49 (1H, d), 7.81-7.86 (1H, d), 8.11-8.15 (2H, d, J=8.4), 8.25-8.29 20 (2H, d, J=8.4), 10.01 (1H, br s, NH); m/z (EI) 295 (M<sup>+</sup>), 278, 263, 246, 130, 102.

(b) 2nd Stage - Preparation of Methyl 2-(4'-cyanophenyl)-1-H-benzimidazole-4-carboxylate

25 Following standard procedure B, methyl 2-amino-3-N-(4'-cyanobenzoyl)aminobenzoate (301mg, 1.02 mmol) from 1st stage was heated in glacial acetic acid (10ml). The product was obtained by recrystallising twice using petrol 40/60 / ethyl acetate. (203mg, 72%)  
30 mp 195-198°C;  $\nu_{\text{max}}$ (cm<sup>-1</sup>) 3447.66, 2228.84, 1691.90, 1288.11  $\delta_{\text{H}}$  4.09 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 7.44-7.53 (1H, t), 7.97-8.01 (1H, d), 8.10-8.13 (2H, d, J=8.4), 8.58-8.62 (2H, d, J=8.4), 12.8 (1H, br s); m/z (EI) 277 (M<sup>+</sup>), 245, 217

35 (c) 3rd Stage - Preparation of 2-(4'-Cyanophenyl)-1-H-benzimidazole-4-carboxamide (NU1092)

Following standard procedure C, methyl 2-(4'-cyanophenyl)-1-H-benzimidazole-4-carboxylate (169.5mg, 0.612 mmol) was treated with ammonia under pressure. The

crude product was recrystallised from boiling methanol to yield the title compound pure as white crystals. (116.5mg, 73%)

mp >310°C; Found C 67.81 H 3.89 N 20.87, C<sub>15</sub>H<sub>10</sub>N<sub>4</sub>O.0.2  
5 MeOH Requires C 67.95 H 4.05 N 20.85; v<sub>max</sub>(cm<sup>-1</sup>) 3332.27,  
3274.86, 3177.98, 2230.85, 1658.54, 1608.10; δ<sub>H</sub> 7.45-7.49  
(1H, t); 7.87-7.91 (1H, d), 7.91 (1H, br s), 7.98-8.02  
(1H, d); 8.13-8.17 (2H, d, J=8.3), 8.50-8.54 (2H, d,  
J=8.3), 9.2-9.4 (1H, br s), 13.6-13.8 (1H, br s); m/z  
10 (EI) 262 (M<sup>+</sup>), 245, 217, 102.

EXAMPLE 11

2 - (4' - Nitrophenyl) - 1 - H - benzimidazole - 4 - carboxamide  
15 (NU1091)

(a) 1st Stage - Preparation of Methyl 2-amino-3-N-(4'-nitrobenzoyl)aminobenzoate

20 Following standard procedure A, methyl 2,3-diaminobenzoate (300mg, 1.807 mmol), dry triethylamine (276.6μl, 1.988 mmol) and DMAP (11mg) were dissolved in dry THF (12ml). To this was added 4-nitrobenzoyl chloride (335.2mg, 1.807 mmol) in dry THF (12ml). Column  
25 chromatography with dichloromethane/methanol 99:1 followed by recrystallisation from methanol gave the product pure.

mp 196-197°C; Found C 57.08 H 3.78 N 13.25 C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>5</sub>  
Requires C 57.14 H 4.12 N 13.33; v<sub>max</sub>(cm<sup>-1</sup>) 3382.31,  
30 3293.01, 3256.56, 1702.05, 1657.83, 1525.37; δ<sub>H</sub> 3.94 (3H,  
s, CO<sub>2</sub>CH<sub>3</sub>), 6.70-6.78 (1H, t), 6.66 (2H, br s, NH<sub>2</sub>),  
7.48-7.51 (1H, d), 7.83-7.87 (1H, d), 8.33-8.38 (2H, d,  
J=8.8), 8.46-8.51 (2H, d, J=8.8), 10.15 (1H, br s, NH);  
m/z (EI) 315 (M<sup>+</sup>), 297, 265, 165.

35

(b) 2nd Stage - Preparation of Methyl 2-(4'-Nitrophenyl)-1-H-benzimidazole-4-carboxylate

Following standard procedure B, methyl 2-amino-3-N-(4'-nitrobenzoyl)aminobenzoate (340.2mg, 1.08 mmol) was

heated in glacial acetic acid (10ml) for 15 minutes. The product was obtained pure by recrystallisation from methanol. (208mg, 65%).

mp 208-210°C; Found C 60.69 H 3.57 N 13.96 C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>O<sub>4</sub>

5 Requires 60.61 H 3.70 N 14.14;  $\nu_{\text{max}}$ (cm<sup>-1</sup>) 3433.70, 1720.14, 1601.84, 1513.07;  $\delta_{\text{H}}$  4.21 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 7.57-7.65 (1H, t), 8.10-8.12 (1H, d), 8.23-8.27 (1H, d), 8.60-8.64 (2H, d, J=8.8), 8.78-8.82 (2H, d, J=8.8), 13.04 (1H, br s, NH); m/z (EI) 297 (M<sup>+</sup>), 265.

10

(c) 3rd Stage - Preparation of 2-(4'-Nitrophenyl)-1-H-benzimidazole-4-carboxamide (NU1091)

Following standard procedure C, methyl 2-(4'-nitrophenyl)-1-H-benzimidazole-4-carboxylate was dissolved in liquid ammonia and heated under constant volume in a pressure vessel. The product was purified by column chromatography from dichloromethane/methanol 99:1 and recrystallised from methanol.

mp >310°C;  $\delta_{\text{H}}$  7.48-7.56 (1H, t), 7.90-7.94 (1H, d), 8.00 (1H, s, NH), 8.00-8.04 (1H, d), 8.52-8.56 (2H, d, J=8.8), 8.60-8.64 (2H, d, J=8.8), 9.3-9.4 (1H, br s, NH), 13.8-14.0 (1H, br s, NH)

EXAMPLE 12

25

2-(3'-Trifluoromethylphenyl)-1-H-benzimidazole-4-carboxamide (NU1093)

(a) 1st Stage - Preparation of Methyl 2-amino-3-N-(3'-trifluoromethylbenzoyl)aminobenzoate

Following standard procedure A, methyl 2,3-diaminobenzoate (200mg, 1.205 mmol), dry triethylamine (704μl, 5.06 mmol) and dimethylaminopyridine (DMAP, 7.3mg) were dissolved in dry THF (7.5ml). To this was added 3-trifluoromethylbenzoyl chloride (183 μl, 1.205 mmol) in dry THF (7.5ml). Column chromatography with dichloromethane/methanol 99:1 removed impurities and the more polar product was eluted with dichloromethane /methanol 97:3. Recrystallisation from methanol gave

the product as a white solid. (160.4mg, 26%).  
mp 157-159°C; Found C 57.14 H 3.57 N 8.10 C<sub>16</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>  
Requires C 56.80 H 3.85 N 8.28; v<sub>max</sub>(cm<sup>-1</sup>) 3368.48,  
3283.82, 2953.87, 1705.98, 1650.77, 1250.02; δ<sub>H</sub> 3.93 (3H,  
5 s, CO<sub>2</sub>CH<sub>3</sub>), 6.69-6.77 (1H, t), 6.73 (2H, s, NH<sub>2</sub>), 7.45-  
7.49 (1H, d), 7.82-7.92 (2H, m), 8.06-8.10 (1H, d), 8.40-  
8.44 (1H, d), 8.48 (1H, s, 2'-H), 10.1 (1H, s, NH); m/z  
(EI) 338 (M<sup>+</sup>), 320, 288, 260, 173, 145.

10 (b) 2nd Stage - Preparation of Methyl 2-(3'-trifluoro-  
methylphenyl)-1-H-benzimidazole-4-carboxylate  
acetate salt

Following standard procedure B, a glacial acetic acid (6ml) solution of methyl 2-amino-3-N-(3'-trifluoromethylbenzoyl)aminobenzoate was heated for 15 minutes. Removal of the solvent under reduced pressure followed by drying at high vacuum yielded the product as a pure white solid. (154.2mg, 96%).

mp 105-107°C; Found C 56.93 H 3.78 N 7.32  
20 C<sub>16</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>.CH<sub>3</sub>CO<sub>2</sub>H Requires C 56.84 H 3.95 N 7.37  
v<sub>max</sub>(cm<sup>-1</sup>) 3438.30, 3339.14, 2959.13, 1707.99, 1328.24,  
1313.53; δ<sub>H</sub> 2.01 (3H, s, CH<sub>3</sub>CO<sub>2</sub>H), 4.09 (3H, s, CO<sub>2</sub>CH<sub>3</sub>),  
7.44-7.51 (1H, t), 7.79-8.13 (4H, m), 8.71-8.75 (1H, d),  
8.82 (1H, s), 11.8-12.2 (1H, br s), 12.8-13.0 (1H, br s);  
25 m/z (EI) 320 (M<sup>+</sup>-CH<sub>3</sub>CO<sub>2</sub>H), 288, 260.

(c) 3rd Stage - Preparation of 2-(3'-trifluoromethyl  
phenyl)-1-H-benzimidazole-4-carboxamide  
(Compound NU1093)

30 Following standard procedure C, the acetate salt of methyl 2-(3'-trifluoromethylphenyl)-1-H-benzimidazole-4-carboxylate (134.8mg, 0.358 mmol) was treated with excess liquid ammonia in a sealed vessel. The product was purified by recrystallisation from methanol, to yield  
35 off-white needles. (78mg, 72%).

mp 268-270°C; Found C 57.68 H 3.82 N 12.96  
C<sub>15</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O.0.6CH<sub>3</sub>OH Requires C 57.74 H 3.82 N 12.95;  
v<sub>max</sub>(cm<sup>-1</sup>) 3488.83, 3348.86, 3176.45, 1667.66, 1600.93,  
1329.63; δ<sub>H</sub> 7.44-7.52 (1H, t), 7.88-8.04 (5H, m), 8.66-

8.70 (1H, d), 8.70 (1H, s, 2' H), 9.3 (1H, br s, NH), 13.6 (1H, br s, NH); m/z (EI) 305 (M<sup>+</sup>), 288, 260, 145.

EXAMPLE 13

5

2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide  
(NU 1098)

10 (a) 1st Stage - Preparation of Methyl 2-amino-3-N-(3'-methoxybenzoyl)aminobenzoate

Following standard procedure A, a solution of methyl 2,3-diaminobenzoate (670.3mg, 4.038 mmol), dry triethylamine (842.6 µl, 6.057 mmol) and DMAP (25mg) in dry THF (20ml) was prepared. A solution of 3-methoxybenzoyl chloride (567 µl, 6.038 mmol) in dry THF (20ml) was added to this. The resulting solid residue was purified by column chromatography using dichloromethane/methanol 99:1 and the product was obtained pure after two recrystallisations from petrol 40/60 / ethyl acetate. (282.6mg, 23%)

mp 124-125°C; Found C 63.90 H 5.11 N 9.24 C<sub>16</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> Requires C 64.0 H 5.33 N 9.33; ν<sub>max</sub>(cm<sup>-1</sup>) 3386.19, 3292.38, 1697.97, 1586.87, 1520.79, 1250.27; δ<sub>H</sub> 3.92 (3H, s), 3.93 (3H, s), 6.61 (2H, s, NH<sub>2</sub>), 6.68-6.76 (1H, t), 7.22-7.27 (1H, d), 7.44-7.47 (1H, d), 7.49-7.57 (1H, t), 7.66 (1H, s, 2'-H), 7.67-7.71 (1H, d), 7.79-7.84 (1H, d), 9.8 (1H, s, NH); m/z (EI) 300 (M<sup>+</sup>), 283, 135, 107.

30 (b) 2nd Stage - Preparation of Methyl 2-(3'-methoxyphenyl)-1-H-benzimidazole-4-carboxylate Acetate Salt

Following standard procedure B, methyl 2-amino-3-N-(3'-methoxybenzoyl)aminobenzoate (356.9mg, 1.19 mmol) was warmed in glacial acetic acid (12ml. The removal of the solvent under reduced pressure followed by recrystallisation with petrol 40/60 / ethyl acetate afforded the title compound pure. (235.6mg, 58%)

mp 93-94°C; Found C 62.66 H 5.13 N 8.06 C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>.CH<sub>3</sub>CO<sub>2</sub>H Requires C 63.16 H 5.26 N 8.18

$\nu_{\text{max}}$  (cm<sup>-1</sup>) 3453.23, 3375.10, 1706.75, 1257.40;  $\delta_{\text{H}}$  1.99 (3H, s, CH<sub>3</sub>CO<sub>2</sub>H), 3.96 (3H, s), 4.06 (3H, s), 7.15-7.21 (1H, d), 7.38-7.46 (1H, t), 7.51-7.59 (1H, t), 7.91-8.00 (3H, m), 8.04-8.08 (1H, d), 12.0 (1H, s), 12.5 (1H, s);  
5  $m/z$  (EI) 282 (M<sup>+</sup>-CH<sub>3</sub>CO<sub>2</sub>H), 250.

(c) 3rd Stage - Preparation of 2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide (NU1098)

Following standard procedure C, a liquid ammonia  
10 solution of methyl 2-(3'-methoxyphenyl)-1-H-benzimidazole-4-carboxylate (203mg, 0.596 mmol) was heated under constant volume. The solid residue was recrystallised from methanol to give the pure product (73.5mg, 46%).  
15 mp 223-225°C; Found C 67.52 H 4.91 N 15.62 C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub> Requires C 67.42 H 4.87 N 15.73;  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 3408.59,  
3388.94, 3168.65, 1662.05, 1625.86, 1603.39;  $\delta_{\text{H}}$  3.99 (3H, s, OCH<sub>3</sub>), 7.22-7.27 (1H, d), 7.43-7.51 (1H, t), 7.58-7.66 (1H, t), 7.85-8.01 (5H, m), 9.4-9.5 (1H, br s), 13.5 (1H, br s);  $m/z$  (EI) 267 (M<sup>+</sup>), 250.

EXAMPLE 14

2-(2'-trifluoromethylphenyl)-1-H-benzimidazole-4-carboxamide (NU1104)

(a) 1st Stage - Preparation of Methyl 2-amino-3-N-(2'-trifluoromethylbenzoyl)aminobenzoate

Following standard procedure A, methyl 2,3-diaminobenzoate (564mg, 3.4 mmol) in a THF (20ml) solution with triethylamine (709μl, 5.1 mmol) and dimethylaminopyridine (21mg) was stirred and to this was added a THF (20ml) solution of 2-trifluoromethylbenzoyl chloride. The resulting oily residue was absorbed onto silica and then subjected to column chromatography with dichloromethane/methanol 99:1 as eluant. The product was obtained pure after recrystallisation from petrol 40/60 / ethyl acetate. (303mg, 26%).  
mp 163-166°C; Found C 56.91 H 3.75 N 8.29 C<sub>16</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>

Requires C 56.80 H 3.85 N 8.28;  $\nu_{\text{max}}(\text{cm}^{-1})$  3329.85, 3243.90, 2955.52, 1696.66, 1663.58, 1312.69;  $\delta_{\text{H}}$  3.94 (3H, s,  $\text{CO}_2\text{CH}_3$ ), 6.58 (2H, s,  $\text{NH}_2$ ), 6.74-6.82 (1H, t), 7.57-7.62 (1H, d), 7.79-8.03 (5H, m), 10.0 (1H, s, NH); 5  $m/z$  (EI) 338 ( $M^+$ ), 321, 289, 173, 145.

(b) 2nd and 3rd Stages - Preparation of 2-(2'-trifluoromethyl)-1-H-benzimidazole-4-carboxamide (NU1104)

10

Upon subjecting the product of the 1st stages successively to standard procedures B and C, the title compound was obtained.

15 EXAMPLE 15

2-(4'-Aminophenyl)-1-H-benzimidazole-4-carboxamide (NU1103)

20 (a) 1st Stage - Preparation of Methyl-2-amino-3-N-(4'-aminobenzoyl)aminobenzoate

Methyl-2-amino-3-N-(4'-nitrobenzoyl)aminobenzoate (from 1st stage of Example 11) was suspended in methanol (40ml) and a slurry of 10% palladium catalyst on activated carbon (~50mg) in methanol (10ml) was added to this with stirring under argon. The solution was atmospherically hydrogenated for 2 hours. After filtration through CELITE (Regd. TM) to remove the catalyst the product was obtained by removal of the solvent under reduced pressure to give a white solid which was dried under high vacuum. (204.1mg, 92%).

mp 197-200°C; Found C 62.95 H 5.30 N 14.39  $C_{15}\text{H}_{15}\text{N}_3\text{O}_3$  Requires C 63.16 H 5.26 N 14.73;  $\nu_{\text{max}}(\text{cm}^{-1})$  3472.55, 3374.96, 3348.97, 3283.31, 1694.80, 1613.91;  $\delta_{\text{H}}$  3.94 (3H, s,  $\text{CO}_2\text{CH}_3$ ), 5.87 (2H, s,  $\text{NH}_2$ ), 6.54 (2H, s,  $\text{NH}_2$ ), 6.68-3.73 (2H, d), 6.73-6.76 (1H, t), 7.42-7.47 (1H, d), 7.78-7.82 (2H, d), 9.4 (1H, s, NH); 5  $m/z$  (EI) 285 ( $M^+$ ), 267, 235, 207, 120, 92.

(b) 2nd Stage - Preparation of Methyl 2-(4'-aminophenyl)-1-H-benzimidazole-4-carboxylate Acetate Salt

5 Following standard procedure B, the treatment of methyl 2-amino-3-N-(4'-aminobenzoyl)aminobenzoate (186.5mg, 0.654 mmol) with hot glacial acetic acid (8ml) for 30 minutes yielded the title compound following recrystallisation from petrol 40/60 / ethyl acetate.

10 (113.4mg, 91%)

mp 162-164°C; Found C 62.60 H 5.04 N 12.73

C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>.CH<sub>3</sub>CO<sub>2</sub>H Requires C 62.39 H 5.20 N 12.84;  
ν<sub>max</sub>(cm<sup>-1</sup>) 3450.66, 3369.25, 3254.20, 1692.41, 1607.56,  
1253.80; δ<sub>H</sub> 2.02 (3H, s, CH<sub>3</sub>CO<sub>2</sub>H), 4.08 (3H, s, CO<sub>2</sub>CH<sub>3</sub>),

15 5.81 (2H, s, NH<sub>2</sub>), 6.75-6.80 (2H, d, J=8.6), 7.32-7.40  
(1H, t), 7.83-7.86 (1H, d), 7.93-7.97 (1H, d), 8.08-8.13  
(2H, d, J=8.6), 11.9 (1H, s), 12.1 (1H, br s); m/z (EI)

267

(M<sup>+</sup>-CH<sub>3</sub>CO<sub>2</sub>H), 235, 207, 92, 60.

20

(c) 3rd Stage - Preparation of 2-(4'-Aminophenyl)-1-H-benzimidazole-4-carboxamide (NU1103)

Following standard procedure C, the acetate salt of  
25 methyl 2-(4'-aminophenyl)-1-H-benzimidazole-4-carboxylate (113mg, 0.346 mmol) was treated with liquid ammonia under pressure for 24 hours. The pure title compound was isolated with column chromatography of the crude material using dichloromethane/methanol 90:10 (21.4mg, 25%)

30 mp 237-240°C; δ<sub>H</sub> 5.90 (2H, s, NH<sub>2</sub>), 6.79-6.83 (2H, d,  
J=8.3), 7.31-7.39 (1H, t), 7.71-7.75 (1H, d), 7.84 (1H,  
s, NH), 7.88-7.92 (1H, d), 8.00-8.04 (2H, d, J=8.3), 9.5-  
9.6 (1H, br s, NH), 13.0 (1H, br s, NH).

ASSAY FOR PARP INHIBITORY ACTIVITY

Compounds of the present invention, particularly those detailed in the preceding Examples, have been 5 tested in vitro for activity as PARP inhibitors using the following methods and materials.

In principle, the PARP assay used relies upon activating endogenous PARP (as hereinafter described) in 10 cells containing exogenous [<sup>32</sup>P]-NAD<sup>+</sup> introduced therein by suspending the cells in a solution of [<sup>32</sup>P]-NAD<sup>+</sup> to which they have been rendered permeable in an initial pre-treatment step. The poly(ADP-ribose) which is then 15 synthesised by the enzyme can be precipitated by trichloroacetic acid (TCA) and the amount of radio-labelled <sup>32</sup>p incorporated therein measured, e.g. using a scintillation counter, to give a measure of the activity of the PARP under the particular conditions of the experiment. By repeating the experiment following the 20 same procedure, and under the same conditions, in the presence of each compound to be tested the reduction in enzyme activity, representative of the inhibitory effect of the test compound, can then be ascertained from the reduction, if any, of the amount of [<sup>32</sup>P] measured in the 25 TCA precipitated poly(ADP-ribose).

The results of this assay may be expressed in terms of percentage inhibition or reduction in activity for one or more different concentrations of each compound tested, 30 or it may be expressed in terms of that concentration of the tested compound which reduces the enzyme activity by 50%, i.e. the IC<sub>50</sub> value. Thus, with a range of different compounds a set of comparative values for inhibitory activity can be obtained.

35

In practice, L1210 murine leukaemia cells have been used as a source of the PARP enzyme after being rendered permeable to exogenous [<sup>32</sup>P]NAD by exposure to hypotonic buffer and cold shock. In the preferred technique which

has been found to give exact and reproducible results, a defined amount of a small synthetic oligonucleotide, in particular a single strand oligonucleotide having the palindromic sequence CGGAATTCCG, is introduced into the  
5 cell suspension for activating the PARP enzyme. This oligonucleotide sequence snaps back on itself to form a double-stranded molecule with a single blunt end and provides an effective substrate for activation of PARP. Its behaviour as a potent activator of the enzyme was  
10 confirmed in the tests carried out.

The experimental protocol adopted, in which a synthetic oligonucleotide as mentioned above is introduced as a specific activator of PARP, discriminates  
15 between PARP and other mono-ADP-ribosyltransferases in the cells. Thus, introduction of such synthetic oligonucleotides causes a 5 to 6 fold stimulation in the radioactive label incorporated and this is attributable solely to PARP activity.  
20

Further details of the assay are given below.

#### Materials

25 The materials used included the following:

##### DTT (Dithiothreitol)

A 100mM (15.4mg/ml) solution (for use as an anti-oxidant) was made up, divided into 500 $\mu$ l aliquots  
30 and stored at -20°C.

##### Hypotonic buffer:

9mM Hepes	(214mg/100ml)
4.5% Dextran	(4.5g/100ml)
4.5mM MgCl <sub>2</sub>	(92mg/100ml)

35

The above ingredients were dissolved in about 80ml distilled water, pH was adjusted to 7.8 (NaOH/HCl), the solution was then made up to 100ml with distilled water, and stored in a refrigerator.

DTT was added to 5mM just before use (50 $\mu$ l/ml).

Isotonic buffer:

	40mM Hepes	(1.9g/200ml)
5	130mM KCl	(1.94g/200ml)
	4% Dextran	(8g/200ml)
	2mM EGTA	(152mg/200ml)
	2.3mM MgCl <sub>2</sub>	(94mg/200ml)
	225mM Sucrose	(15.39g/200ml)

10

The above ingredients were dissolved in about 150ml distilled water, pH was adjusted to 7.8 (NaOH/HCl), the solution was then made up to 200ml with distilled water and stored in a refrigerator.

15

DTT was added to 2.5mM just before use (25 $\mu$ l/ml).

NAD

20 NAD was stored as a solid in pre-weighed aliquots at -20°C. From these, solutions of a concentration of approximately 6mM (4-4.5mg/ml) were freshly made up shortly before performing an assay, and the molarity was checked by measuring the optical density (O.D.) at 260nm. The stock solution was then diluted with water to give a 25 concentration of 600 $\mu$ M and a small amount of <sup>32</sup>P labelled NAD was added (e.g. 2-5 $\mu$ l/ml).

Oligonucleotide

30 The oligonucleotide having the palindromic sequence CGGAATTCCG, synthesised by conventional means, was vacuum dried and stored as pellets in a freezer. Before use, it was made up to 200 $\mu$ g/ml in 10mM Tris/HCl, pH 7.8, with each pellet being dissolved completely in 50ml of buffer. The 35 solution was then heated to 60°C in a water bath for 15 minutes, and allowed to cool slowly to ensure correct reannealing. After adding 9.5ml of buffer, the concentration was checked by measuring the optical density of a diluted sample at 260nm.

The main solution was then diluted to a concentration of 200 $\mu$ g/ml and stored in 500 $\mu$ l aliquots in a freezer, ready for use.

5

TCA

Solutions of TCA (Trichloroacetic acid) were prepared at two concentrations. 10% TCA + 10% sodium pyrophosphate, and 1% TCA + 1% sodium pyrophosphate.

10

Cells

15

The L1210 cells used as the source of the PARP enzyme were maintained as a suspension culture in RPMI medium + 10% foetal bovine serum + glutamine and antibiotics (penicillin and streptomycin). HEPES and sodium bicarbonate were also added, and the cells were seeded in 100ml-200ml of medium such that there would be a concentration of approximately 8 x 10<sup>5</sup>/ml at the time of carrying out an assay.

20

Method

The compounds being tested were generally made up as a concentrated solution in DMSO (Dimethyl sulphoxide). 25 The solubility of the compound was then checked by adding a quantity of the DMSO solution to a quantity of the isotonic buffer, in the required final proportions that were to be used in carrying out the assay, and after an interval the solution was examined under a microscope for 30 any signs of crystals forming.

A desired quantity of the cells, ascertained by counting with a haemocytometer, was then centrifuged (1500rpm in a "Europa" model 24M centrifuge for 5 35 minutes), the supernatant removed, and the pellets obtained were resuspended in 20ml Ca<sup>++</sup> Mg<sup>++</sup> free phosphate buffered saline (Dulbeco's modification A, abbreviated Dul A) at 4°C before centrifuging again at 1500rpm and 4°C. After again removing the supernatant,

the cells were resuspended at a concentration of  $3 \times 10^7$  cells/ml in ice cold hypotonic buffer and left for 30 minutes on ice. Nine volumes were then added of ice cold isotonic buffer, and the cells, now rendered permeable to 5 exogenous NAD<sup>+</sup>, were then used within the next hour for carrying out an assay. The permeabilisation of the cells may be checked at this stage by adding duplicate aliquots of cells to an equal volume of trypan blue, leaving for 5 minutes and then counting on a haemocytometer. Those 10 rendered permeable will take up the Trypan blue and appear coloured.

The assay was then carried out using for convenience plastic 15ml conical bottomed assay tubes set 15 up in a shaking water bath at 26°C which is the optimum temperature for this enzyme. In a typical assay using the oligonucleotide solution at a concentration of 5µg/ml and the test compound/DMSO solution at a concentration of 2%, and carrying out the assay in quadruplicate, there 20 would then be placed in each assay tube 5µl of the oligonucleotide solution, 50µl of the 600µm NAD + [32P]-NAD solution, 8µl of the test compound/DMSO solution, and 37µl of water. Prior to the start of the experiment this "cocktail" would be pre-warmed for 7 minutes at 26°C, as 25 would be also the cell suspension. The reaction would then be started by adding 300µl of the cell suspension. The reaction would be stopped by adding 2ml of the ice-cold 10% TCA + 10% sodium pyrophosphate solution.

30 In addition to the above, six assay tubes would usually be set up as blanks, these containing the same ingredients as above but, before adding the cell suspension, TCA solution is added to prevent any reaction from taking place. This enables corrections to be 35 applied for any non-specific binding of the labelled material to the filter used (see below).

After adding the cell suspension at timed intervals to each of the assay tubes, the 10% TCA + 10% sodium

pyrophosphate at 4°C was added to each assay tube exactly 5 minutes after addition of the cell suspension to that tube. Then, after leaving the tubes on ice for a minimum time of one hour, the contents of each individual tube 5 were filtered through an individual filter funnel of a suction filter apparatus using GF/C filter elements (rough side up) wetted with 10% TCA. After filtering the contents of each tube and rinsing the filters several times with 1% TCA + 1% sodium pyrophosphate solution, the 10 filters were carefully removed and dried before being placed in individual scintillation vials. Four additional scintillation vials were also set up as reference standards containing 10 $\mu$ l of the 600 $\mu$ M NAD + [ $^{32}$ P]-NAD solution, 10ml scintillant then being added to 15 each vial. Counting was carried out for 2 minutes on a  $\beta$  counter to obtain measures of the  $^{32}$ P present, and thus the amount of the poly(ADP-ribose) and activity of the PARP enzyme.

20 RESULTS OF IN VITRO PARP INHIBITION STUDIES

Apart from applying the PARP enzyme assay in accordance with the standard procedure outlined above to a range of compounds which have been made in accordance 25 with the present invention, for comparison purposes it was also applied to certain benzamide compounds, in particular benzamide, 3-hydroxybenzamide and 3-methoxybenzamide, that are already known to exhibit certain PARP inhibitory activity. A tabulated list of 30 some exemplary compounds which have been made and/or studied is hereinafter presented in the TABLE at the end of the present description, together with the PARP inhibition assay results obtained in one or more different experiments, expressed either as the percentage 35 inhibition at a 10 $\mu$ M concentration or, more usually, as IC<sub>50</sub> values, for the compounds when tested using the assay hereinabove described.

In reviewing this list, the known PARP inhibitors

benzamide, 3-aminobenzamide and 3-methoxybenzamide, may be regarded as reference compounds. Although the results varied somewhat, in general the compounds of the present invention which were tested showed a relatively high degree of inhibitory activity. Of especial interest were the benzimidazole carboxamides having the reference numbers NU1064, NU1066, NU1086 and, most particularly, NU1070, NU1076, NU1077, NU1085, NU1090, NU1091, NU1092, NU1093 and NU1098, of which NU1091 and NU1092 showed exceptionally high inhibitory activities.

#### FURTHER BIOLOGICAL ACTIVITY STUDIES

Again using cultures of the murine leukaemia L1210 cell line, growth inhibition experiments were carried out to assess the cytostatic effects of the compounds and clonogenic survival assays were performed to assess cytotoxicity, especially in relation to use of the compounds in conjunction with DNA damaging cytotoxic agents such as cytotoxic antitumour drugs or gamma irradiation. DNA damage and the effect of the PARP inhibitors on the process of DNA strand break formation and repair has also been assessed by carrying out DNA strand break assays and monitoring by alkaline elution in accordance with published techniques.

In the growth inhibition assays, typically the L1210 cells would be seeded at  $1 \times 10^4/\text{ml}$  in triplicate in 24 well multidishes, and 24 hours later the compounds or drugs being tested would be added in selected combinations and concentrations. At this time one set of replicates would be counted using a Coulter counter ( $N_0$ ), and 48 hours later the remaining samples would be counted ( $N_1$ ). The percentage (%) growth inhibition of drug-treated samples could then be estimated. In drug combination experiments, where evidence of synergistic effects on cell growth or clonogenicity was being sought, a single, fixed concentration of a cytotoxic drug sample,

e.g. temozolomide (TM), would be taken as the control value.

Examples of *in vitro* Cytotoxicity Assays

5

In a particular example of an *in vitro* cytotoxicity assay using the compound NU1064 (2-methylbenzimidazole-4-carboxamide), L1210 murine leukaemia cells were incubated with increasing concentrations of NU1064 in the presence 10 or absence of 100 $\mu$ M of the methylating agent, temozolomide, in a final DMSO concentration of 1% DMSO, for 24 hours at 36°C. The cells were pelleted, resuspended in fresh medium, counted and seeded for colony formation in 0.15% agarose in drug-free medium. 15 After 1 week colonies of viable cells were stained with MTT (1ml 0.5mg/ml) and counted. The plating efficiency of the control (89%) and temozolomide alone (32%) were normalised to 100% relative survival and the plating efficiency of the NU1064-treated cells expressed as a 20 percentage of these values.

There was a modest reduction in cell survival caused by NU1064 alone (relative plating efficiency at 100 $\mu$ M and 200 $\mu$ M NU1064 = 72% and 54%, respectively) but a 25 very marked increase in temozolomide cytotoxicity with increasing concentrations of NU1064 (relative plating efficiency at 100 and 200 $\mu$ M NU1064 = 28% and 2%, respectively) indicating a NU1064-concentration-related potentiation of temozolomide cytotoxicity. An 30 illustration of these results is presented by FIG. 1 of the accompanying drawing.

In other, clonogenic survival, assays, typically the L1210 cells would be exposed to varying 35 concentrations of TM  $\pm$  a fixed concentration of PARP inhibitor for a fixed time of 16 hours, prior to counting and seeding for colony formation in 0.12-0.15% agarose in drug-free medium. After 7-10 days colonies would be stained with 0.5mg/ml MTT and counted by eye on a gridded

light box. This then enables survival curves to be plotted and DEF<sub>10</sub> values to be obtained, DEF<sub>10</sub> being defined as the ratio of the concentration of TM that reduces survival to 10% divided by the concentration of  
5 TM that reduces survival to 10% in the presence of a fixed concentration of PARP inhibitor.

In further clonogenic survival assays gamma ray irradiation may be used to damage the cells. Typically,  
10 L1210 cells (3ml, 4 x 10<sup>3</sup>/ml in plastic bijoux bottles) would be irradiated at 4°C with varying doses of gamma rays in the presence or absence of the compound being tested and a final concentration of 2% DMSO. The cells would then be incubated at 37°C for 2 hours in the  
15 continued presence or absence of PARP inhibitor prior to seeding for colony formation.

Repair of potentially lethal damage (PLD) occurs when cells are held in stationary-phase following  
20 initiation of PLD prior to allowing cell division to take place. In further typical experiments to test potential PARP inhibitors, L1210 cells have been allowed to repair gamma ray PLD in the presence or absence of the test compound as follows: L1210 cells were maintained in  
25 culture until they had attained stationary phase (>10<sup>6</sup>cells/ml). They were diluted to 1.5 x 10<sup>5</sup>/ml in conditioned medium from stationary-phase cultures to prevent further cell division. Replicate 2ml samples of cells in plastic bijoux were held on ice prior to and  
30 immediately following 8 Gray gamma ray irradiation. 1ml of 3x final concentration of the test compounds made up in conditioned medium from stationary cultures would then be added to give appropriate final concentrations (e.g. 10<sup>6</sup>cells/ml in 1% DMSO ± test compounds), and the cells  
35 would be incubated at 37°C for 0, 2 or 4 hours prior to resuspending in drug-free medium and seeding for colony formation. Unirradiated stationary phase cultures incubated at 37°C for 0, 2 or 4 hours with 1% DMSO ± the same amount of test compound provide appropriate controls

for determining relative cell survival. In the absence of PARP inhibitor cell survival would normally increase with time allowed for PLD repair to take place. For example, in one set of experiments, when seeded 5 immediately after irradiation (no repair) only about 0.2% of the cells survived, but after a 4 hour repair period this had increased to 0.7%. An effective PARP inhibitor blocks this repair, thus reducing the survival rate.

10 With regard to the DNA strand break assays previously mentioned, typically samples of L1210 cells would be incubated for a certain time, e.g. 1 hour, with a fixed concentration, e.g. 150 $\mu$ M, of temozolomide and, apart from a control, in the presence of increasing 15 concentrations of the PARP inhibitors tested. The more effective the inhibitor, the greater the rate of the alkaline elution (a measure of extent of strand breakage) compared to temozolomide alone.

20 In general, the studies carried out fully support the belief that the PARP inhibitory characteristics of the compounds tested reflect an ability of these compounds to potentiate the cytotoxicity of DNA damaging agents, such as certain cytotoxic antitumour drugs and 25 radiation used in radiotherapy. Accordingly, having regard to their strong PARP inhibitory characteristics, the compounds of this invention can be expected to be especially useful for administration in conjunction with such cytotoxic drugs or radiotherapy in order to 30 potentiate the cytotoxic effect of the latter in the course of medical treatment as hereinbefore indicated.

#### Summary

35

Although the present invention should be regarded overall as comprising each and every novel feature or combination of features disclosed herein, the main aspects of the invention comprise, principally but not

exclusively, broadly the following:-

- (i) Novel compounds of formula (I) as defined herein;
- 5 (ii) Compounds of formula (I) with substituents as hereinbefore defined (including pro-drug forms and salts thereof) for therapy or for use in medicine and in the manufacture of medical preparations, useful for example as PARP inhibitors to be  
10 administered in conjunction with cytotoxic drugs or with radiotherapy to potentiate the effectiveness of the latter in treatment of cancer;
- 15 (iii) Processes for the preparation of novel compounds of formula (I) as defined herein, including any novel intermediate compounds produced in carrying out such processes;
- 20 (iv) Pharmaceutical formulations comprising a compound of formula (I) as defined herein together with a pharmaceutically acceptable carrier therein; and
- 25 (v) Processes for the preparation of a pharmaceutical formulation as defined in (iv) above, e.g. by methods referred to herein.


30

35

House No.	Name	Structure	% Inhibition at 10 µM or IC <sub>50</sub> value
Ref	benzamide  C <sub>7</sub> H <sub>7</sub> O  MW = 121.1		IC <sub>50</sub> = 12.4 ± 3.1 µM
Ref	3-hydroxybenzamide  C <sub>7</sub> H <sub>7</sub> NO <sub>2</sub>  MW = 137		IC <sub>50</sub> = 8.0 ± 3.5 µM (7)
Ref	3-methoxybenzamide  C <sub>8</sub> H <sub>9</sub> NO <sub>2</sub>  MW = 151		55
NU1064	2-methylbenzimidazole-4-carboxamide  C <sub>9</sub> H <sub>9</sub> N <sub>3</sub> O  MW = 175.38		IC <sub>50</sub> = 1.09 ± 0.23 µM (3)
NU1066	benzimidazole-4-carboxamide  C <sub>8</sub> H <sub>7</sub> N <sub>3</sub> O  MW = 161.16		IC <sub>50</sub> = 1.26 µM  IC <sub>50</sub> = 1.02 µM
NU1067	benzimidazole-4-carboxylic acid  C <sub>8</sub> H <sub>6</sub> N <sub>2</sub> O <sub>2</sub>  162.14		Inactive
NU1070	2-phenylbenzimidazole-4-carboxamide  C <sub>14</sub> H <sub>11</sub> N <sub>3</sub> O  237.26		IC <sub>50</sub> = 92 nM  IC <sub>50</sub> = 103 nM

NU1076	2-(4-methoxyphenyl) benzimidazole-4- carboxamide  $C_{15}H_{13}N_3O_2$ 267.28		$IC_{50} = 59 \text{ nM}$
NU1077	2-(4-trifluoro- methylphenyl) benzimidazole-4- carboxamide  $C_{15}H_{10}N_3OF_3$ 305.25		$IC_{50} = 75 \text{ nM}$
NU1085	2-(4-hydroxyphenyl) benzimidazole-4- carboxamide  $C_{14}H_{11}N_3O_2$ 253.26		$IC_{50} = 77 \text{ nM}$
NU1086	2-trifluoromethyl- benzimidazole-4- carboxamide  $C_{16}H_{15}N_3O_2$ 281.31		$IC_{50} = 1.6 \mu\text{M}$
NU1090	2-(4-methoxyphenyl)- <i>N</i> - methylbenzimidazole-4- carboxamide  $C_{16}H_{15}N_3O_2$ 281.31		$IC_{50} = \sim 100 \text{ nM}$
NU1091	2-(4-nitrophenyl)- benzimidazole-4- carboxamide  $C_{14}H_{10}N_4O_3$ 282.25		$IC_{50} = 22 \text{ nM}$


NU1092	2-(4-cyanophenyl)-benzimidazole-4-carboxamide  C <sub>14</sub> H <sub>10</sub> N <sub>4</sub> O  262.27		IC <sub>50</sub> = 33 nM
NU1093	2-(3-trifluoromethyl-phenyl)benzimidazole-4-carboxamide  C <sub>15</sub> H <sub>10</sub> N <sub>3</sub> OF <sub>3</sub>  305.25		IC <sub>50</sub> = 76 nM
NU1098	2-(3-methoxyphenyl)benzimidazole-4-carboxamide  C <sub>15</sub> H <sub>13</sub> N <sub>3</sub> O <sub>2</sub>  267.28		IC <sub>50</sub> = 130 nM
NU1101	N-benzoyl-2-(4-methoxyphenyl)-benzimidazole-4-carboxamide  C <sub>22</sub> H <sub>17</sub> N <sub>3</sub> O <sub>3</sub>  371.39		IC <sub>50</sub> = 0.27 μM
NU1103	2-(4-aminophenyl)-benzimidazole-4-carboxamide  C <sub>14</sub> H <sub>12</sub> N <sub>4</sub> O  252.27		IC <sub>50</sub> = 91 nM
NU1104	2-(2-trifluoromethyl-phenyl)benzimidazole-4-carboxamide  C <sub>15</sub> H <sub>10</sub> N <sub>3</sub> OF <sub>3</sub>  305.25		Not tested

NU1105	<i>N</i> -carboxybenzyl-2-(4-methoxyphenyl)-benzimidazole-4-carboxamide  $C_{23}H_{19}N_3O_4$ 401.42		1.9 $\mu$ M
--------	---	--	-------------

CLAIMS

1. Use of a compound as herein defined for the manufacture of a medical or veterinary preparation for  
 5 use in therapy for inhibiting activity of the enzyme poly(ADP-ribose)polymerase or PARP (also known as ADP-ribosyl transferase or ADPRT), such enzyme inhibition constituting an element of a therapeutic treatment, said compound providing the active PARP enzyme inhibiting  
 10 agent and being a benzimidazole-4-carboxamide having the general structural formula I

15



I

20

or a pharmaceutically acceptable salt and/or pro-drug form thereof,

25

characterised in that in structural formula I

30

R is selected from hydrogen, alkyl, hydroxyalkyl (e.g. CH<sub>2</sub>CH<sub>2</sub>OH), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group,  
 and

R' is selected from hydrogen, alkyl, hydroxyalkyl (e.g. CH<sub>2</sub>CH<sub>2</sub>OH), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group.


35

2. Use of a compound as claimed in Claim 1 wherein the or each alkyl group present, either as such or as a moiety in an alkoxy or other group, contains 1-6 carbon atoms.

3. Use of a compound as claimed in Claim 1 or 2  
wherein

5 R represents an optionally substituted  
phenyl group having the structural formula  
II

10

**II**

15

20


wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>9</sub> are each selected  
independently from H, hydroxy, alkoxy,  
NO<sub>2</sub>, N<sub>3</sub>, NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub> and R<sub>6</sub> each being  
independently hydrogen, alkyl or  
alkoxy), NHCOR<sub>3</sub> (R<sub>3</sub> being alkyl or  
aryl), CO<sub>2</sub>R<sub>4</sub> (R<sub>4</sub> being H or alkyl), an  
amide (e.g. CONH<sub>2</sub>), tetrazole, alkyl,  
hydroxyalkyl, CW<sub>3</sub> or W (W being  
halogen), and CN.

4. Use of a compound as claimed in Claim 3 wherein R<sub>1</sub>  
25 is a group other than hydrogen and is in the 4'-position,  
and wherein R<sub>2</sub> and R<sub>9</sub> are each hydrogen.

5. Use of a compound as claimed in any of the  
preceding claims wherein

30 R' represents an optionally substituted  
phenyl group having the structural formula  
III

35

**III**

wherein R<sub>7</sub>, R<sub>8</sub> and R<sub>10</sub> are each selected independently from H, hydroxy, alkoxy, NO<sub>2</sub>, N<sub>3</sub>, NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub> and R<sub>6</sub> each being independently hydrogen, alkyl or alkoxy), NHCOR<sub>3</sub> (R<sub>3</sub> being alkyl or aryl), CO<sub>2</sub>R<sub>4</sub> (R<sub>4</sub> being H or alkyl), an amide (e.g. CONH<sub>2</sub>), tetrazole, alkyl, hydroxyalkyl, CW<sub>3</sub> or W (W being halogen), and CN.

10

6. Use of a compound as claimed in Claim 5 wherein R<sub>7</sub> is a group other than hydrogen and is in the 4'-position, and wherein R<sub>8</sub> and R<sub>10</sub> are each hydrogen.

15

7. Use of a compound as claimed in Claim 1 wherein R is selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl and cyclohexyl.

20

8. Use of a compound as claimed in Claim 1 wherein R' is hydrogen or alkyl and R is phenyl or benzyl having at least one substituent in the benzene ring which is selected from hydroxy, alkoxy, NO<sub>2</sub>, N<sub>3</sub>, NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub> and R<sub>6</sub> each being independently hydrogen, alkyl or alkoxy), NHCOR<sub>3</sub> (R<sub>3</sub> being alkyl or aryl), CO<sub>2</sub>R<sub>4</sub> (R<sub>4</sub> being H or alkyl), an amide (e.g. CONH<sub>2</sub>), tetrazole, alkyl, hydroxyalkyl, CW<sub>3</sub> or W (W being halogen), and CN.

9. Use of a compound as claimed in Claim 1 which compound is one of the following:

30

- (a) 2-methylbenzimidazole-4-carboxamide;
- (b) benzimidazole-4-carboxamide;
- (c) 2-phenylbenzimidazole-4-carboxamide;
- (d) 2-(4'-methoxyphenyl)benzimidazole-4-carboxamide;
- (e) 2-(4'-trifluoromethylphenyl)benzimidazole-4-
- 35 carboxamide;
- (f) 2-(4'-hydroxyphenyl)benzimidazole-4-carboxamide;
- (g) 2-trifluoromethylbenzimidazole-4-carboxamide;
- (h) 2-(4'-methoxyphenyl)-N-methylbenzimidazole-4-carboxamide;

- (i) 2-(4'-nitrophenyl)benzimidazole-4-carboxamide;
- (j) 2-(4'-cyanophenyl)benzimidazole-4-carboxamide;
- (k) 2-(3'-trifluoromethylphenyl)benzimidazole-4-carboxamide;

5       (l) 2-(3'-methoxyphenyl)benzimidazole-4-carboxamide;

- (m) 2-(4'-methoxyphenyl)-1-N-benzoylbenzimidazole-4-carboxamide,
- (n) 2-(4'-aminophenyl)benzimidazole-4-carboxamide
- (o) 2-(2'-trifluoromethylphenyl)benzimidazole-4-carboxamide,

10      (p) *N*-carboxybenzyl-2-(4'-methoxyphenyl)-benzimidazole-4-carboxamide.

10. Use of a compound as claimed in any of the  
15 preceding claims wherein the compound is in the form of a pro-drug having a substituent group selected from phosphate, carbamate and amino acid.


11. Use of a compound as claimed in Claim 10 wherein  
20 the pro-drug form is a phosphate derivative of a compound having the general structural formula I.

12. Use of a compound as claimed in Claim 11, said compound being in the form of a phosphate pro-drug  
25 provided by a water-soluble ammonium or alkali metal phosphate salt derived from a compound of structural formula I that has at least one hydroxyl group substituent.

30 13. Use of a compound as claimed in Claim 12 wherein the compound of structural formula I from which the phosphate pro-drug is derived has a hydroxyl group substituent that is reacted with a dibenzyl phosphonate.

35 14. For use in therapy as an active pharmaceutical substance, a benzimidazole compound having the general structural formula I

5

**I**

or a pharmaceutically acceptable salt and/or pro-drug  
10 form thereof,


characterised in that in structural formula I

15 R is selected from hydrogen, alkyl, hydroxyalkyl  
(e.g. CH<sub>2</sub>CH<sub>2</sub>OH), acyl (e.g. acetyl or benzoyl) or  
an optionally substituted aryl (e.g. phenyl) or  
aralkyl (e.g. benzyl or carboxybenzyl) group,  
subject to the proviso that R is not 4'-  
methanesulphonyloxy-2'-methoxy-phenyl,  
20 and

R' is selected from hydrogen, alkyl, hydroxyalkyl  
(e.g. CH<sub>2</sub>CH<sub>2</sub>OH), acyl (e.g. acetyl or benzoyl) or  
an optionally substituted aryl (e.g. phenyl) group.

25 15. A compound having the general structural formula I

30

**I**

35 or a pharmaceutically acceptable salt thereof,

wherein

R is selected from hydrogen, alkyl, hydroxyalkyl

(e.g.  $\text{CH}_2\text{CH}_2\text{OH}$ ), acyl (e.g. acetyl or benzoyl) or a substituted aryl (e.g. a substituted phenyl) group or an optionally substituted aralkyl (e.g. benzyl or carboxybenzyl) group,

5 and

R' is selected from hydrogen, alkyl, hydroxyalkyl (e.g.  $\text{CH}_2\text{CH}_2\text{OH}$ ), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) group,

10 subject to the proviso that R is not 4'-methanesulphonyloxy-2'-methoxy-phenyl.


16. A compound as claimed in Claim 10 or 11 wherein the or each alkyl group present, either as such or as a  
15 moiety in an alkoxy or other group, contains 1-6 carbon atoms.

17. A compound as claimed in Claim 14, 15 or 16 wherein

20

R represents an optionally substituted phenyl group having the structural formula II

25



30

wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>9</sub> are each selected independently from H, hydroxy, alkoxy, NO<sub>2</sub>, N<sub>3</sub>, NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub> and R<sub>6</sub> each being independently hydrogen, alkyl or alkoxy), NHCOR<sub>3</sub> (R<sub>3</sub> being alkyl or aryl), CO<sub>2</sub>R<sub>4</sub> (R<sub>4</sub> being H or alkyl), an amide (e.g. CONH<sub>2</sub>), tetrazole, alkyl, hydroxyalkyl, CW<sub>3</sub> or W (W being halogen), and CN.

35

18. A compound as claimed in Claim 17 wherein R<sub>1</sub> is a group other than hydrogen and is in the 4'-position, and wherein R<sub>2</sub> and R<sub>9</sub> are each hydrogen.


5

19. A compound as claimed in any of Claims 14 to 18 wherein

10

R' represents an optionally substituted phenyl group having the structural formula III

15

**III**

20

wherein R<sub>7</sub>, R<sub>8</sub> and R<sub>10</sub> are each selected independently from H, hydroxy, alkoxy, NO<sub>2</sub>, N<sub>3</sub>, NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub> and R<sub>6</sub> each being independently hydrogen, alkyl or alkoxy), NHCOR<sub>3</sub> (R<sub>3</sub> being alkyl or aryl), CO<sub>2</sub>R<sub>4</sub> (R<sub>4</sub> being H or alkyl), an amide (e.g. CONH<sub>2</sub>), tetrazole, alkyl, hydroxyalkyl, CW<sub>3</sub> or W (W being halogen), and CN.

25

20. A compound as claimed in Claim 19 wherein R<sub>7</sub> is a group other than hydrogen and is in the 4'-position, and wherein R<sub>8</sub> and R<sub>10</sub> are each hydrogen.

30

21. A compound as claimed in Claim 14 or 15 wherein R is selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl and cyclohexyl.

22. A compound as claimed in Claim 14 or 15 wherein R'

is hydrogen and R is either a phenyl or a benzyl group having at least one substituent in the benzene ring which is selected from hydroxy, alkoxy, NO<sub>2</sub>, N<sub>3</sub>, NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub> and R<sub>6</sub> each being independently hydrogen, alkyl or alkoxy), 5 NHCO<sub>3</sub> (R<sub>3</sub> being alkyl or aryl), CO<sub>2</sub>R<sub>4</sub> (R<sub>4</sub> being H or alkyl), an amide (e.g. CONH<sub>2</sub>), tetrazole, alkyl, hydroxyalkyl, CW<sub>3</sub> or W (W being halogen), and CN.

23. A compound as claimed in Claim 14 or 15 which is 10 one of the following:

- (a) 2-methylbenzimidazole-4-carboxamide;
- (b) benzimidazole-4-carboxamide;
- (c) 2-(4'-methoxyphenyl)benzimidazole-4-carboxamide;
- (d) 2-(4'-trifluoromethylphenyl)benzimidazole-4-15 carboxamide;
- (e) 2-(4'-hydroxyphenyl)benzimidazole-4-carboxamide;
- (f) 2-trifluoromethylbenzimidazole-4-carboxamide;
- (g) 2-(4'-methoxyphenyl)-N-methylbenzimidazole-4- carboxamide;
- 20 (h) 2-(4'-nitrophenyl)benzimidazole-4-carboxamide;
- (i) 2-(4'-cyanophenyl)benzimidazole-4-carboxamide;
- (j) 2-(3'-trifluoromethylphenyl)benzimidazole-4- carboxamide;
- (k) 2-(3'-methoxyphenyl)benzimidazole-4-carboxamide;
- 25 (l) 2-(4'-methoxyphenyl)-1-N-benzoylbenzimidazole-4- carboxamide,
- (m) 2-(4'-aminophenyl)benzimidazole-4-carboxamide
- (n) 2-(2'-trifluoromethylphenyl)benzimidazole-4- carboxamide,
- 30 (o) N-carboxybenzyl-2-(4'-methoxyphenyl)- benzimidazole-4-carboxamide.

24. A compound as claimed in any of Claims 14 to 23 wherein the compound is suitable for oral or intravenous 35 therapeutic administration and is in the form of a pro-drug having a substituent group selected from phosphate, carbamate and amino acid.

25. A compound as claimed in Claim 24 wherein the pro-

drug form is a phosphate derivative of a compound having the general structural formula I.

26. A compound as claimed in Claim 25, said compound  
5 being in the form of a phosphate pro-drug provided by a water-soluble ammonium or alkali metal phosphate salt derived from a compound of structural formula I that has at least one hydroxyl group substituent.

10 27. A compound as claimed in Claim 26 wherein the compound of structural formula I from which the phosphate pro-drug is derived has a hydroxyl group substituent that is reacted with a dibenzyl phosphonate.

15 28. A process for preparing a compound as claimed in Claim 17 comprising the steps of reacting an alkyl 2,3-diaminobenzoate with an aryl acid chloride, treating the product with acetic acid at an elevated temperature to bring about benzimidazole ring formation, and reacting 20 with liquid ammonia to form the amide derivative.

29. A compound as claimed in any one of Claims 14 to 27 for use in therapy as an active PARP-inhibiting substance.

25

30. Use of a compound as claimed in any one of Claims 14 to 27 for the manufacture of a medical or veterinary preparation for use in therapeutic treatment of a mammal.

30

31. A pharmaceutical formulation or composition containing a compound as claimed in Claim 29 in unit dosage form made up for administration to a mammal likely to benefit from treatment with a PARP-inhibiting agent in the course of therapy.

35

32. A pharmaceutical formulation or composition for medical use comprising an effective PARP-inhibiting amount of a compound as claimed in any one of Claims 14 to 27 together with a pharmaceutically acceptable

carrier.

33. A pharmaceutical formulation or composition as claimed in Claim 31 or 32 for use in conjunction with 5 cytotoxic agents or radiotherapy in antitumour treatment.

34. A pharmaceutical composition containing an effective PARP inhibiting amount of a compound as claimed in Claim 29 in admixture with a therapeutically useful 10 and effective amount of a cytotoxic drug for use in antitumour treatment.

35. A method of therapeutic treatment carried out on a mammal wherein inhibition of activity of PARP enzyme is 15 considered likely to be beneficial, said method comprising administering to said mammal an effective PARP-inhibiting amount of a compound as claimed in any one of Claims 14 to 27.

20 36. A method as claimed in Claim 35 carried out in conjunction with administration of a DNA-damaging cytotoxic drug or radiotherapy in the course of antitumour therapy.


25

30

35

L1210 Cell Clonogenic Assay  
NU1064 +/- 100 $\mu$ M Temozolomide  
(1% DMSO)

FIG. 1



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 96/01832

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/415 C07D235/06

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J.CHEM.SOC., PERKIN TRANS. 1, no. 9, 1979, pages 2303-2307, XP000605168 T.L.GILCHRIST ET AL.: "Cyclisation of ortho-Substituted N-Arylbenzimidoyl Nitrenes. Part 2. Preferential Cyclisations at an ortho-Position Bearing a Methoxycarbonyl Group" see page 2303 see page 2305 ---	17
X	J.MED.CHEM., vol. 36, no. 12, June 1993, pages 1772-1784, XP000605166 K.KUBO ET AL.: "Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Benzimidazoles" see table 1 ---	1-36
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

9 October 1996

Date of mailing of the international search report

29.10.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl  
Fax (+ 31-70) 340-3016

Authorized officer

Theuns, H

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 96/01832

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE,A,35 22 230 (DR. KARL THOMAE GMBH) 2 January 1987 see the whole document see page 7, line 58 - line 63 ---	1-36
X	EP,A,0 425 921 (TAKEDA CHEMICAL INDUSTRIES LTD.) 8 May 1991 see the whole document ---	1-36
X	EP,A,0 420 237 (EISAI CO., LTD.) 3 April 1991 see the whole document ---	1-36
A	US,A,5 338 744 (DUDLEY ET AL.) 16 August 1994 see column 1, line 47 - column 2, line 9 ---	1-36
A	WO,A,90 03181 (MEDICAL RESEARCH COUNCIL) 5 April 1990 see page 3, line 13 - line 17 ---	1-36
A	WO,A,95 06410 (SMITHKLINE BEECHAM CORPORATION) 9 March 1995 see page 2, line 35 - page 3, line 10 -----	1-36

**INTERNATIONAL SEARCH REPORT****I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark: Although claims 35 - 36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr. Application No.

PCT/GB 96/01832

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
DE-A-3522230	02-01-87	AU-A-	5893286	24-12-86
		EP-A-	0209707	28-01-87
		JP-A-	62000471	06-01-87
<hr/>				
EP-A-0425921	08-05-91	AT-T-	126219	15-08-95
		AU-B-	649418	26-05-94
		AU-A-	6461290	02-05-91
		CA-A-	2028302	25-04-91
		DE-D-	69021502	14-09-95
		DE-T-	69021502	11-01-96
		FI-A-	954554	26-09-95
		NO-B-	177304	15-05-95
		RU-C-	2023713	30-11-94
		US-A-	5128356	07-07-92
		US-A-	5250554	05-10-93
		CN-A,B	1051355	15-05-91
		JP-A-	4009373	14-01-92
<hr/>				
EP-A-0420237	03-04-91	AT-T-	134998	15-03-96
		AU-B-	641685	30-09-93
		AU-A-	6307590	11-04-91
		CA-A-	2026533	30-03-91
		CN-A,B	1050539	10-04-91
		DE-D-	69025687	11-04-96
		DE-T-	69025687	08-08-96
		EP-A-	0598702	25-05-94
		EP-A-	0628557	14-12-94
		ES-T-	2085876	16-06-96
		FI-B-	94527	15-06-95
		FI-A-	945147	01-11-94
		JP-A-	3236377	22-10-91
		JP-A-	7224059	22-08-95
		NO-B-	176912	13-03-95
		RU-C-	2024521	15-12-94
		US-A-	5328911	12-07-94
		US-A-	5298518	29-03-94
		US-A-	5506238	09-04-96
<hr/>				
US-A-5338744	16-08-94	US-A-	5444069	22-08-95
		CA-A-	2093125	03-04-92

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/GB 96/01832

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-5338744		EP-A-	0551432	21-07-93
		JP-T-	6502168	10-03-94
		WO-A-	9205784	16-04-92
-----	-----	-----	-----	-----
WO-A-9003181	05-04-90	AU-A-	4324089	18-04-90
-----	-----	-----	-----	-----
WO-A-9506410	09-03-95	AU-A-	7833594	22-03-95
		EP-A-	0724387	07-08-96
-----	-----	-----	-----	-----